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As an organ system, the lung has unique advantages and disadvantages for direct 
drug delivery. Its contact with the external environment allows for the airways to be 
easily accessible to intrapulmonary delivery. However, its complex structure, which 
divides into more narrow airways with each branch, can make direct delivery to the 
remote alveoli challenging. The objective of this thesis was to overcome this issue by 
using exogenous surfactant, a lipoprotein complex used to treat neonatal respiratory 
distress syndrome, as a carrier for pulmonary therapeutics. It was hypothesized that 
therapeutics administered with a surfactant vehicle would display enhanced delivery 
to the deeper regions of the lung. Acute respiratory distress syndrome and bacterial 
pneumonia were selected as prototypical examples of pulmonary conditions in which 
surfactant-drug combinations may be beneficial. Consequently, the pharmaceuticals 
utilized were those with antibacterial or anti-inflammatory activities.  
To test this hypothesis, the wet bridge transfer system was developed in Chapter 
2 as a novel in vitro screening tool for surfactant-based therapeutics. Several antibiotic 
and anti-inflammatory medications combined with a commercially available exogenous 
surfactant were screened based on 1) surfactant spreading and 2) the biological efficacy 
of the transported drug at a remote site. In Chapter 3 this platform, in combination with 
other in vitro techniques, were utilized to gain the mechanistic insight required for 
optimizing surfactant vehicle prior to animal studies. Specifically, through these 
experiments a synthetic surfactant was designed, such that, the antibacterial activity of 
cathelicidins, a family of potent antimicrobial peptides, was retained when transported to 





efficacy of this delivery approach for a mainstay anti-inflammatory. Surfactant based 
delivery was found to downregulate of a wide variety of inflammatory markers across 
both sexes. 
To conclude, surfactant-based delivery of antimicrobial and anti-inflammatory 
therapeutics was found to enhance drug delivery and efficacy at remote sites in vitro as 
well as in vivo. Based on these findings, it is also suggested that future research expand 
on the optimization process of this thesis for other surfactant-drug preparations and assess 
those combinations in clinically relevant animal models.  
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Summary for Lay Audience 
The branching structure of the lung makes direct drug delivery to its more remote 
regions challenging. The objective of this thesis was to overcome this delivery issue by 
using exogenous surfactant as a carrier for drugs targeting the lung. It was hypothesized 
that drugs administered with a surfactant would show enhanced delivery to the 
more remote regions of the lung. Although many lung conditions could benefit from 
this approach, this thesis focused on: acute respiratory distress syndrome (Lung 
Inflammation) and bacterial pneumonia (Lung Infection). Consequently, the drugs 
explored were those with the ability to kill bacteria and downregulate inflammation.  
To test this hypothesis, the wet bridge transfer system was developed in Chapter 
2 as a new screening tool for surfactant-drug mixtures. It was used to screen several 
antibiotic and anti-inflammatory medications that were combined with an exogenous 
surfactant, based on 1) surfactant spreading as well as 2) drug efficacy at a remote site. In 
Chapter 3, this platform was combined with other techniques to design a better surfactant 
vehicle for antibacterial peptides, known as cathelicidins. Finally, Chapter 4 used an 
animal model of lung inflammation to assess the effectiveness an anti-inflammatory 
medication delivered by a surfactant vehicle. 
 Together, the findings of this thesis support surfactant as a drug delivery vehicle 
for anti-bacterial and anti-inflammatory medications. It is also recommended that future 
research use the methods outlined in this thesis to design and evaluate surfactant vehicles 
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1.1 General Overview 
The therapeutic efficacy of any given drug is influenced by its ability to reach its 
specific target cell, tissue, or organ. For some organs, such as the skin, accessibility is 
relatively straightforward and topical drug administration can be highly effective with 
limited side-effects. For other, internal organs, such as the liver or kidneys, drug 
administration via systemic routes can be effective but can also be strongly affected by 
drug metabolism and negative side-effects on other organs. Between these two extremes, 
the lung presents itself as an organ system with distinct advantages and disadvantages for 
drug delivery. Its direct contact with the external environment allows for potential 
localized delivery; this, for example, allows for the highly efficient use of inhalers 
(puffers) to administer bronchodilators and anti-inflammatory medications in asthmatics. 
However, localized delivery becomes more difficult for therapeutics that are targeting the 
deeper areas of the lung, in which the extensive branching structure and large surface area 
provide substantial hurdles to adequate drug delivery. This problem gets exacerbated in 
certain lung diseases in which edema fluid, lung collapse and/or tissue remodelling may 
further affect accessibility.  
The purpose of this thesis will be to investigate a potential solution to these latter 
scenarios, namely the use of exogenous surfactant as a vehicle to improve the delivery of 
pulmonary therapeutics. This first chapter will describe the complex branching anatomy 
of the lung and features of exogenous surfactant that would make it ideal for enhancing 
pulmonary drug delivery. It will also outline clinical scenarios, such as bacterial lung 
infections and acute respiratory distress syndrome (ARDS), in which surfactant-based 





the mechanism of action and therapeutic potential of cathelicidins for bacterial lung 
infections and glucocorticoids for ARDS.  
 
1.2 Lung Structure and Function  
The lungs are an essential component of the respiratory system, responsible for 
facilitating gas exchange between the external environment and the bloodstream. 
Specifically, oxygen and carbon dioxide are exchanged at the alveoli, moving across the 
respiratory membrane. These molecules move down their concentration gradients, 
resulting in oxygen diffusing across the epithelia and endothelia into the deoxygenated 
blood within the surrounding alveolar capillaries [1, 2]. Carbon dioxide moves in the 
opposite direction from the blood stream into the alveoli and is eventually exhaled out of 
the body [1]. 
Located within the thoracic cavity, the lungs are enclosed by the rib cage and 
diaphragm. The organ begins as the nasopharynx extends into the trachea, which in turn 
divides into two main bronchi [1, 2]. Figure 1.1A illustrates this complex branching 
structure of the airways, which continues to divide from the two main bronchi into 
smaller and smaller sections, eventually forming the terminal bronchioles [1, 2]. From the 
trachea to the terminal bronchioles, is referred to as the conducting zone [1, 2]. The 
structures within this region are involved in air flow, but do not participate in gas 
exchange. Beyond the terminal bronchioles are the respiratory bronchioles, that diverge 
structurally from their terminal counterparts with the appearance of alveolar sacs [1, 2]. 
This division begins the respiratory zone, which refers to structures involved in gas 





being surrounded by a dense network of capillaries [1, 2]. The unique branching structure 
of the airways provides the lungs with a massive surface area at the level of the alveoli 
and therefore facilitates rapid gas exchange [1, 2].   
As illustrated in Figure 1.1B, there are two main cell types that cover the alveolar 
surface, appropriately named alveolar type I and type II cells. The flat alveolar type I cells 
cover the majority of the alveolar epithelium and facilitate gas exchange [3]. Their large 
surface area and thin structure allow for the efficient diffusion of gas molecules during 
normal respiration [3]. In contrast, the small number of type II alveolar cells cover a 
much smaller portion of the alveolar surface. These cuboidal type II cells contain lamellar 
bodies and are responsible for the production and secretion of pulmonary surfactant [3–
5]. A complex mixture of specialized surfactant proteins and lipids, pulmonary surfactant 
is essential for normal breathing mechanics [4, 5]. Type II alveolar cells are also 
responsible for replacing dysfunctional or damaged type I cells as well as contributing to 
the innate immune defense of the alveolus [3]. Moreover, the alveolus also contains 
resident macrophages that contribute to surfactant metabolism and immune defense, 











1.2.1 Pulmonary ventilation 
To promote gas exchange, air needs to be moved in and out of the lung efficiently. 
This is accomplished by changing the volume of the thoracic cavity, through a process 
known as ventilation. Specifically, the volume is increased and decreased through the 
contraction and relaxation of various respiratory muscles, including the diaphragm and 
external intercostal muscles. As explained by Boyle’s law, increasing or decreasing the 
volume of a closed container, in this case the thoracic cavity, will change its pressure 
gradient with the external atmosphere [2]. Inspiration, or the movement of air into the 
lung occurs through to the coordinated contraction of the diaphragm and external 
intercostal muscles. These contractions expand the volume of the thoracic cavity such that 
the air pressure within the lung is lowered below the air pressure of the external 
environment. At rest, the relaxation of the diaphragm and external intercostal muscles is 
enough to cause the lung to recoil to its original size, promoting expiration or the 
movement of air out of the lung. During exercise, the increased rate of exhalation requires 
the contraction of additional muscles, such as the internal intercostals, oblique and 
abdominal muscles [2]. These additional contractions further decrease the volume of the 
thoracic cavity, creating a larger pressure gradient with the external environment and 
forcing more air out of the lung. 
In addition to the contraction and relaxation of respiratory muscles, ventilation is 
also affected by distensibility [2]. This property, known as lung compliance, refers to the 
volume to which the lungs expand per unit of air pressure change [2]. Thus, a lung with 
low compliance requires a greater amount of force or work from the breathing muscles to 





the elastic properties of the lung tissue and 2) the surface tension within the alveoli [2]. 
The elasticity of the lung tissue is based on the flexibility of its structural components. 
Specifically, the amount of collagen or elastin fibers that are meshed inside the airway 
interstitium regulate this aspect of lung compliance [2]. For example, the more collagen 
the greater the elastic resistance of the lung and therefore the greater the force required to 
cause the lung to expand. Surface tension within the lung is created at the air–liquid 
interface by the attractive force between water molecules, in the fluid lining the airways. 
These water molecules pull towards each other, in an attempt to force air out of the 
alveoli, creating a resistance force to the expansion of the region [2]. As such, a high 
surface tension at the alveolar surface results in a low lung compliance. It is the role of 
pulmonary surfactant secreted into this fluid layer to reduce surface tension at the air–
liquid interface (Figure 1.1B) [2, 4, 5]. The surface tension lowering properties of 
surfactant are essential for normal lung function and influence both lung compliance as 
well as alveolar stability [4, 5]. 
 
1.2.2 The pulmonary surfactant system  
As mentioned above, pulmonary surfactant is a lipoprotein mixture produced by 
the alveolar type II cells [4, 5]. The mixture is stored inside of these alveolar cells in 
structures known as lamellar bodies, until it is secreted into the fluid lining the airways 
[4–6]. Pulmonary surfactant then adsorbs through this fluid layer to the air–liquid 
interface. During respiration, the surfactant film reduces surface tension based on its 
concentration at this interface [4, 5]. During exhalation, the surfactant film is compressed 





very low surface tensions (near 0mN/m). However, when the film is expanded or 
becomes less concentrated during inspiration, surfactant reduces surface tension in the 
alveolus to a lesser degree (5-30mN/m) [4, 5]. By reducing surface tension, pulmonary 
surfactant promotes normal lung compliance and prevents alveolar collapse during 
exhalation [4, 5]. The functional components of pulmonary surfactant, that produce the 
surface tension lowering film are collectively known as “large aggregates”. As the surface 
film is compressed and expanded, the process also creates small vesicles of surfactant, 
which will be either taken up by alveolar type II cells for recycling or alveolar 
macrophages for degradation [7]. These vesicles are the inactive components of surfactant 
and are collectively referred to as “small aggregates”.   
Pulmonary surfactant can be isolated from lung lavage material by differential 
centrifugation and the analysis of surfactant from numerous mammalian species has 
revealed a well conserved composition [8, 9]. Approximately 85% of the surfactant 
consists of phospholipids. Phosphatidylcholine (PC) being the most abundant at ~75% of 
the total phospholipid fraction, with more than half this phospholipid being represented 
by the saturated species dipalmitoylphosphatidylcholine (DPPC). Phosphatidylglycerol 
(PG) is the second most abundant phospholipid at ~10%, with other phospholipids, such 
as sphingomyelin and phosphatidylethanolamine, present in lower amounts [4, 8]. In 
addition to phospholipids, surfactant also contains ~5-8% neutral lipids, predominantly 
cholesterol, as well as 7-10% surfactant associated proteins designated SP-A, SP-B and 
SP-C [8, 10]. Of note, a fourth protein, SP-D, has also been identified but is not co-
isolated with the surfactant obtained by centrifugation [11]. The surfactant proteins B and 





surfactant [12, 13]. SP-A and SP-D are also large multimeric glycoproteins of the 
collectin family [14, 15].   
The function of pulmonary surfactant can be broadly divided into two parts, its 
biophysical function [4, 16, 17] and its host defense function [18, 19]. This thesis will 
focus on the biophysical properties of pulmonary surfactant, however its role in host 
defense has been reviewed elsewhere and appears to be mainly mediated through SP-A 
and SP-D [14, 18, 20]. The biophysical role of surfactant consists of forming a surface 
tension reducing lipid film at the air–liquid interface of the alveolar surface, with further 
reduction of this surface tension to near zero mN/m during exhalation when the film is 
compressed as the surface area of the lung decreases [4, 16, 21]. This reduction of surface 
tension stabilizes the lung (i.e. it prevents alveolar collapse) and allows for inflation with 
relative ease.  
 
1.2.3 Biophysical functions of pulmonary surfactant  
The biophysical properties of pulmonary surfactant are mediated through its 
phospholipid components and specialized proteins [4, 16, 21–23]. Specifically, DPPC is 
thought to be mainly responsible for the surface tension lowering properties of pulmonary 
surfactant, while the other lipids and surfactant proteins play a role in the formation and 
maintenance of the surfactant film [4, 16, 21–23].  Briefly, to accomplish its biophysical 
functions, pulmonary surfactant must have enough fluidity to rapidly transfer its surface-
active molecules to the air–liquid interface, and film stability, such that, it can tightly 





Experimentally, the rapid adsorption (i.e. transfer of surface-active components to 
the air–liquid interface) and surface tension lowering properties of pulmonary surfactants 
have been demonstrated in numerous experiments [8, 16]. Often performed using a 
Langmuir probe to measure surface tension, these experiments have found that functional 
surfactants can significantly reduce surface tension to equilibrium values (approx. 23 
mN/m) [8, 16]. Mechanistically, the surface tension reducing properties of pulmonary 
surfactant have been shown to be mediated by its phospholipids (most importantly 
DPPC), which displace water molecules at the air–liquid interface [4, 8, 16, 22, 24, 25]. 
By occupying this interface, these amphipathic phospholipids seem to displace water 
molecules and therefore reduce their collapse or pull force away from air. Although 
monolayer experiments have also shown that liposomes of pure DPPC can reduce surface 
tension to equilibrium values, these liposomes adsorb very slowly relative to natural or 
lipid extract surfactants [24, 25]. These findings suggest that other surfactant components 
are required for the rapid formation of a surfactant film. Notably, SP-B and SP-C have 
been shown to enhance the adsorption and spreading capabilities of lipid mixtures, 
including pure DPPC, in vitro [26–28]. Further, experiments utilizing radioactively 
labelled surfactant lipids have demonstrated the ability of SP-B and SP-C to break stable 
phospholipid bilayers and promote the insertion of lipids into a surface film [28]. 
Additionally, other Langmuir-Wilhelmy studies have found that the level of non-DPPC 
surfactant lipids, including PG, unsaturated PC, and cholesterol, can also affect the ability 
of pulmonary surfactant to adsorb and spread, presumably by affecting film fluidity [29, 
30]. Thus, the rapid adsorption of pulmonary surfactant to equilibrium seems to require 





The ability of pulmonary surfactants to reduce surface tension to even lower 
values (near 0mN/m) during compression has been illustrated by experiments utilizing the 
pulsating, captive, and constrained sessile drop surfactometers (CDS) [16, 31, 32]. This 
further reduction in surface tension during exhalation is thought to be linked to the 
surfactant film being reorganized when compressed, such that, it is enriched in the 
saturated phospholipid DPPC [4, 16, 21–23]. Basically, interfacial compression is 
theorized to cause the “squeeze out” of the more fluid, unsaturated lipids within surfactant 
from the interface, leaving the more solid DPPC. Experimentally, this DPPC refinement 
has been shown to be mediated through SP-B and SP-C, allowing the surfactant film to 
achieve very low surface tensions because DPPC can be tightly packed without 
collapsing, presumably due to its desaturated acyl chains [29, 33]. Mass spectrometry has 
also been used to show the creation of separate DPPC and non-DPPC lipid monolayers 
during surfactant compression [21]. Briefly, the study demonstrated that unsaturated 
phospholipids were “squeezed out” of the surfactant film, leaving a monolayer enriched 
in desaturated phospholipid species [21]. Together, these studies highlight the role of 
surfactant proteins, in addition to DPPC, for the surface tension lowering properties of 
pulmonary surfactant during compression. 
 
1.2.4 Exogenous surfactant therapy 
The origins of exogenous surfactant therapy lie in the discovery of endogenous 
surfactant and the clinical finding of surfactant deficiency in preterm infants, a story 
chronicled in several excellent reviews [34–38]. Briefly, the critical importance of 





dysfunction observed in preterm infants with surfactant deficiency [35, 38]. This 
condition, termed neonatal respiratory distress syndrome (NRDS), was a major cause of 
infant mortality until the mid-1980’s at which time clinical trials showed the efficacy of 
exogenous surfactant therapy [38, 39]. Intratracheal administration of a purified version 
of animal surfactants was found to significantly increase survival in this vulnerable 
patient population [40–43]. As such, exogenous surfactant is currently standard therapy in 
neonatal intensive care units (ICU) [44].  
The success of exogenous surfactant in NRDS prompted investigations of this 
therapy in other lung conditions, most notably ARDS [45, 46]. ARDS can be caused by a 
variety of initiating insults and is defined by severe lung dysfunction [47–49]. This 
physiological impairment of lung function showed similarities with observations in 
NRDS. However, whereas NRDS can be diagnosed immediately at the onset of the injury 
and is due to surfactant deficiency [35, 38], ARDS is diagnosed later in the disease 
process when injury is well-established and is associated with surfactant impairments [17, 
50, 51]. Nevertheless, the similarities prompted extensive research into exogenous 
surfactant therapy for this disease [52–55]. Unfortunately, the initial clinical trials and 
subsequent meta-analysis of the data did not indicate an improvement in mortality due to 
surfactant therapy in ARDS [46, 56–61]. Specifically, these clinical trials found that the 
benefits of surfactant therapy for ARDS patients were largely limited to improvements in 
blood oxygenation. However, as stated in a recent review by Veldhuizen et al., the 
emergence of severe acute respiratory syndrome coronavirus 2 (COVID-19) related 
ARDS has prompted a reconsideration of this clinical approach [62]. Specifically, 
researchers have begun to re-examine the negative results of these early trials with respect 





role of exogenous surfactant in the treatment of ARDS has also been revaluated to include 
(among other approaches), its potential as a drug delivery vehicle [62]. These new 
insights into the potential role of exogenous surfactant for treating ARDS as well as the 
limitations of previous trials, have led to five ongoing clinical trials of surfactant therapy 
for COVID-19 patients [62]. 
 
1.2.4.1 Animal derived and synthetic exogenous surfactant preparations 
Underlying the above information on the clinical utilization of exogenous 
surfactants is, obviously, the extensive research and development to produce these 
therapeutics. The general composition of a select number of currently available 
preparations is shown in Table 1. The most frequently utilized surfactants are the animal 
derived preparations obtained from lung lavage material from cattle or pigs [63, 64]. 
These exogenous surfactants undergo a lipid extraction with organic solvents and as such 
contain the surfactant lipids as well as the two hydrophobic proteins (SP-B & SP-C). A 
second type of animal derived exogenous surfactant can be created through the extraction 
of minced lung tissue with supplementation of DPPC and palmitic acid to enhance the 
spreadability of the material [65–67]. These preparations contain surfactant proteins B 
and C, although in lower amounts compared to lavage derived surfactants. Additionally, 
several synthetic surfactant preparations have also been produced. In general, these 
synthetic surfactants contain DPPC, PG, and some other lipids, as well as components 
that allow the lipids to spread [68–73]. In the most promising artificial surfactants, these 
components are analogues of surfactant proteins B and/or C, such as Mini-B or the 
synthetic peptoids [72, 73]. For example, CHF5633, a newly developed synthetic 





have similar clinical efficacy for treating NRDS compared to an animal derived surfactant 
[74]. Thus, the high efficacy of these synthetic analogues have made the most recent 
artificial surfactants viable, low cost, and highly versatile alternatives to animal derived 
surfactant replacements [72–74].  
Regardless of the preparation method and specific composition, the functional 
characteristics, as required for the treatment of NRDS, are similar. An exogenous 
surfactant should be able to adsorb onto, and spread along, an air–liquid interface, 
reflective of its ability to distribute throughout the lung when instilled as a bolus liquid. 
During dynamic compression and expansion cycles these surfactants should be able to 
reach low surface tension of below 5 mN/m, indicative of the ability to reduce the surface 
tension at the alveolar wall during inhalation and exhalation to facilitate ventilation with 






Table 1.1. Compositions of various exogenous surfactant preparations. 





















DPPC 32% 31% 33% 37% 65% 100% 70% 75% 50% 
Unsat PC 50% 45% 53% 37% 22% 0% 0% 0% 0% 
PG 9% 6% 11% 1% 3% 0% 30% 25% 50% 
Other 
phospholipids 
9% 18% 3% 25% 10% 0% 0% 0% 0% 
Neutral 
lipid 
Cholesterol Cholesterol Cholesterol FFA 
Cholesterol 
FFA 















    
Synthetic 
Additives 









Phospholipids are expressed as reported averages as a percentage of total phospholipids. See text for references. DPPC: 
dipalmitoyl phosphatidylcholine; Unsat PC: Unsaturated phosphatidylcholine; PG: phosphatidylglycerol; FFA: free fatty acids; 
SP: surfactant protein. Other phospholipids within these surfactants may include phosphatidylserine, 





1.3 Exogenous Surfactant as a Drug Delivery Vehicle 
The successful treatment of inflammatory or infection-based conditions of the lower 
respiratory tract, require medications to achieve adequate therapeutic concentrations at 
the alveoli. Unfortunately, this is made particularly difficult by the complex branching 
structure of the airways (i.e. becoming more narrow with each division) as well as airway 
collapse associated with these conditions [1, 75–78]. Despite this delivery issue, the 
administration of therapeutics directly to sites of infection or inflammation within the 
lung has numerous benefits over systemic dosing, including increased therapeutic 
concentrations within the lung and reduced risk of systemic toxicity [79–81]. This 
concept is best illustrated by the low toxicity and high therapeutic efficacy of aerosolized 
glucocorticoids in the treatment of asthma [82–84]. Unfortunately, along with aerosolized 
antibiotics, these inhaled medications tend to accumulate in the central airways, limiting 
their ability to reach peripheral sites of infection or inflammation [76, 81, 83]. Thus, other 
direct delivery methods need to be explored to enhance bioavailability at peripheral sites, 
while limiting side effects [85, 86]. 
The overall concept of exogenous surfactant as a pulmonary drug delivery agent is 
relatively straightforward and originates from the success of exogenous surfactant therapy 
as utilized in conditions such as NRDS [40–44]. Briefly, intratracheally administered 
exogenous surfactants can adsorb and spread at the air–liquid interface of the airways. 
This allows exogenous surfactants to distribute throughout the lung, reaching and 
reducing surface tension at the alveoli (see section 1.2.2 The pulmonary surfactant 
system). Its ability to spread to the alveoli, when administered intratracheally, inspired the 





therapeutics and other compounds [62, 77, 87–89]. The basic premise is that when 
combined, exogenous surfactant will facilitate the delivery of a compound to the remote 
areas of the lung.  
A few studies have tested this concept experimentally by directly evaluating 
pulmonary drug distribution. For instance, studies have utilized fluorescently or 
radioactively label therapeutics to evaluate the distribution of surfactant-drug mixtures in 
vivo [89, 90]. One such study, utilized excised hamster lungs that were sliced into 3-mm 
cross sections, to quantify the distribution of a radioactively labelled version of 
pentamidine following intratracheal instillation with saline or an exogenous surfactant. 
Utilizing an exogenous surfactant as a carrier for the radioactively labelled compound 
resulted in radioactivity being detectable in more of the lung slices (93%) compared to 
saline (72%) [89]. The radioactivity was also detectable over a larger fraction of the lung 
slices analyzed, when the compound was instilled with surfactant (43%) compared to 
saline (21%). The study concluded that exogenous surfactant not only resulted in a more 
uniform distribution of the anti-infective agent, but that it also delivered the drug to a 
greater portion of the lung [89]. A similar distribution study in rats, used a radioactively 
labelled version of dexamethasone to quantify drug levels in both the lung and circulation 
following administration via either intratracheal instillation or intravenous injection [91]. 
For intratracheal instillation, the use of an exogenous surfactant as a carrier for 
dexamethasone resulted in significantly greater lobar delivery compared to saline, with 
radioactivity being associated with the small airways and alveoli of the lung [91]. 
Together, this published data demonstrates the enhanced pulmonary distribution that 





Another characteristic of exogenous surfactant that supports its usage as a pulmonary 
delivery vehicle, is its safety. The utilization of any therapeutic, including exogenous 
surfactants, in a patient population requires controlled clinical trials to examine the 
efficacy and safety of the therapy. Although some care needs to be taken with surfactant 
preparations to avoid the formation of stable bubbles capable of blocking airways, no 
major negative side effects have been reported for surfactant administration. This includes 
not only the evidence from its utilization in NRDS [40–43], but also the data on safety 
obtained in the various ARDS trials [46, 56–60]. The safety and toxicology of the 
selected drugs to be utilized with surfactant would vary among all compounds. However, 
the premise of surfactant-based drug administration is lung targeted delivery, which 
would further limit potential side effects associated with systemic administration.  
Despite its origins for treating NRDS, it should also be noted that the drug carrier 
approach for exogenous surfactant targets a different clinical outcome than the simple 
restoration of the surfactant system. As such, there are clear distinctions that need to be 
considered for this approach. First, it is imperative that the therapeutic that is mixed with 
the exogenous surfactant associates with the surfactant but does not inhibit its ability to 
spread throughout the lung. It is also important that the exogenous surfactant’s ability to 
reduce surface tension is maintained to open areas of the lungs that are collapsed. The 
opening up of these collapsed lung units would allow these injured areas to become 
accessible for the delivered drug. Conversely, it is similarly important that the function of 
the drug being delivered to the lung is maintained in the presence of the exogenous 
surfactant and that the drug reaches its intended target. The development of a new in vitro 





the basis for our wet bridge transfer system, described in Chapter 2. In addition, the 
assessment of a surfactant-based therapeutic in vivo is the basis of Chapter 4. 
Lastly, based on the additional variables associated with surfactant-drug 
combinations, these compounds may require the use of newly designed synthetic 
surfactants. For example, whereas animal derived surfactants are utilized extensively, and 
successfully, for surfactant treatments for NRDS, these preparations have a defined lipid-
protein composition (Table 1.1). Interaction of a potential therapeutic with surfactant can 
be affected by that composition. As such, there may be scenarios in which synthetic 
surfactants are more suitable for drug delivery purposes. In general, synthetic surfactants 
are more amendable to altering the specific composition and could therefore be optimized 
for surfactant-carrier interactions. This concept of designing a synthetic surfactant for a 
specific therapeutic is explored in Chapter 3. Further, although each specific therapeutic- 
surfactant combination will require a targeted research approach, a general overview of 







Figure 1.2. Schematic summary of surfactant-based drug development. 
 
1.4 Respiratory Conditions that Could Benefit from 
Surfactant-based Therapeutics  
Throughout this literature review, we have explored many preclinical studies that 
highlighted the ability of exogenous surfactants to facilitate the distribution of 
antibacterial and anti-inflammatory agents to remote regions within the lung. Moreover, 
surfactant as a drug carrier has been used clinically, to treat preterm babies at risk for the 
development of bronchopulmonary dysplasia (BPD) [92–95]. BPD is a chronic lung 
disease which develops in premature infants, especially those exposed to prolonged 
ventilation and high oxygen. In two controlled clinical trials, the effect of an exogenous 
surfactant, Survanta, with budesonide was compared to surfactant alone with respect to its 





provided by the two clinical trials has been analyzed in a systematic review and meta-
analysis which concluded that intra-tracheal administration of budesonide-surfactant 
mixtures decreased the incidence of BPD [96, 97]. However, considering the limited 
number of trials to date, both by the same team of investigators and with the same 
surfactant preparation, both papers also indicated the need for additional large clinical 
trials prior to recommending this approach as a standard therapy.  
Whereas these clinical trials for BPD provide the first proof-of-principle for this 
delivery approach in patients, the clinical utilization of a surfactant-drug combination in 
other conditions is lagging. Notably, the expansion of promising preclinical data for 
therapeutics delivered by a surfactant vehicle in the treatment of bacterial pneumonia and 
ARDS.   
 
1.4.1 Bacterial lung infections  
Bacterial pneumonia is an infection of the lower respiratory tract and the leading 
cause of death due to infection worldwide [98]. The World Health Organization estimates 
that pneumonia accounts for approximately 15% of deaths under the age of 5, and 3.2 
million deaths annually [98–101]. These statistics encompass a diverse range of 
conditions including community-acquired pneumonia, ventilator associated pneumonia 
(VAP), hospital-acquired pneumonia, cystic fibrosis, as well as pneumonia resulting from 
complications of other diseases [98, 99, 102–105]. The current treatment paradigm for 
bacterial lung infections involves the administration of high-dose oral or systemic 
antibiotics [105–107], however, additional treatment strategies are required to overcome 





The rationale for using exogenous surfactant-based therapies to treat this respiratory 
condition was outlined, in general, in a previous section (see section 1.3 Exogenous 
Surfactant as a Drug Delivery Vehicle) and includes the need for localized delivery in the 
deeper areas of the lung [75]. Simply put, the clearance of a bacterial infection requires 
adequate antibiotic concentrations at the site of infection. Consequently, the sublethal 
pulmonary bioavailability from oral, systemic, or aerosolized medications may, in fact, be 
partly responsible for another hurdle in the treatment of these infections, the increasing 
incidence of antimicrobial resistance (AMR) [76, 81, 104, 108–111]. Moreover, the 
problem of AMR is not limited to lung infections as it is considered one of the largest 
current and future threats to global health in general [112–114]. Complicating treatment 
further, chronic inflammation associated with lung infections also contributes to the 
adverse outcomes in bacterial pneumonia [98, 106, 115, 116]. For example, in CF and 
VAP patients, the bronchial mucus layer and endotracheal tube, respectively, can act as 
reservoirs for bacteria [103, 106, 107, 117]. Consequently, these reservoirs can prevent 
the host immune system from fully clearing the infection. This leads to a prolonged 
bacterial colonization of the lungs, increased incidence of AMR, and excessive 
inflammation that can damage the respiratory system [103, 106, 107, 117]. Therefore, the 
treatment of bacterial lung infections, may require immunomodulatory therapeutics, in 
addition to new antimicrobial agents.  
Focusing on AMR infections in the lung, it is estimated that nearly 30% of clinical 
pneumonia isolates from ICU or nursing home patients are resistant to three or more 
antibiotics, with pathogens such as Pseudomonas aeruginosa (P. aeruginosa) being 
particularly problematic [98, 118, 119]. Specifically, this gram-negative bacterium has 





antibiotics, including biofilm development as well as increased expression of efflux 
proteins and inactivating enzymes [119, 120]. Additionally, in pneumonia patients 
susceptible to frequent, spontaneous, or chronic infections, their need for prolonged 
antibiotic treatment promotes even higher rates of AMR [117, 121–125]. Notably, these 
spontaneous infections are most commonly caused by P. aeruginosa or Staphylococcus 
aureus (S. aureus), among other pathogens [98, 120]. In conditions such as CF, the 
acquisition of AMR bacteria represents a pivotal stage in disease progression that is 
linked with poor outcomes, due to the limited treatment options available [116, 126]. 
Despite this rising incidence of AMR, there are very few new antibiotics currently being 
developed [98, 127–130]. This has pushed many researchers to explore new sources of 
antimicrobial therapeutics, in addition to new routes of drug delivery [127].  
 
1.4.1.1 Antimicrobial peptides: cathelicidins 
Antimicrobial peptides are found in the innate immune system of almost all 
classes of life [131–133]. Specifically, they represent a diverse group of more than 3000 
distinct and endogenously produced peptides [131–133]. Due to their diversity, 
classification can vary, however antimicrobial peptides are often subdivided based on 
their source, activity, structural characteristics, and amino acid composition [131, 133]. In 
general, antimicrobial peptides are relatively small (under 100 amino acids) and 
positively charged [131, 133]. This thesis will focus on one of the main categories of 
mammalian antimicrobial peptides, cathelicidins, which were utilized in our studies 
(Table 1.2)[131]. 
Cathelicidins are a family of antimicrobial peptides present in the innate immune 





[137, 138], and mice [139] (among many others) [140]. Almost all epithelial or immune 
cells contain a cathelicidin, with the highest concentrations being found in neutrophils 
[140–142]. Within immune cells, the N-terminal sequence is responsible for the 
movement of the inactive peptide into storage units known as secretory granules, at which 
point the sequence is removed [140, 143, 144]. When immune cells interact with a 
inflammatory marker, microbe, or pathogen that requires an immune response the 
secretory vesicles are released [140, 143, 144]. Then a specific protease cleaves the 
“cathelin” domain, allowing for the mature cathelicidin to elicit its antimicrobial and 
immunomodulatory functions [140, 143, 144]. This family of peptides derives its name 
from a 99 to 114 amino acid pro-sequence, referred to as the “cathelin” domain; a region 
with close homology to cathelin (the cathepsin L inhibitor) [140]. This domain is highly 
conserved across species, however it is only found in the inactive, pro-peptide [140]. The 
full-length pro-peptide contains an N-terminal signalling sequence, the “cathelin” 
domain, and a short antimicrobial domain at the C-terminus [140, 145]. The biologically 
active cathelicidin will consist of this small (12 to 100 amino acids) C-terminal sequence, 
which displays very high interspecies and intraspecies diversity [140, 144, 145]. 
Consequently, mature cathelicidins are quite diverse in their structure, net charge, amino 
acid sequence length and/or composition, as well as antimicrobial or immunomodulatory 





Table 1.2. Characteristics of cathelicidins explored in this thesis. 





E. coli S. aureus LPS LTA 
CRAMP ISRLAGLLRKGGEKIGEKLKKIGQKIKNFFQKLVPQPE 38 +6 One α-helix 9 hrs 0.5 hrs 5 µM 20 µM 
LL-37 LLGDFFRKSKEKIGKEFKRIVQRIKDFLRNLVPRTES 37 +6 One α-helix 10 µM 0.5 hrs 1.25 µM 0.31 µM 
CATH-2 RFGRFLRKIRRFRPKVTITIQGSARF-NH2 26 +9 
Two α-helices 
connected by 
a proline hinge 
5 µM 2.5 µM 5 µM 1.25 µM 
PMAP-23 RIIDLLWRVRRPQKPKFVTVWVR 23 +6 
Two α-helices 
connected by 
a proline hinge 
9.5 hrs 20 µM >20 µM 20 µM 
*Antimicrobial activity refers to the cathelicidin concentration (0.33-20 μM) that significantly delayed bacterial growth (1x106 
CFU/ml) of E. coli or S. aureus for a minimum of 10 hours in Mueller Hinton Broth [147]. If this could not be achieved, hours 
of growth delay for 20µM was depicted instead. +Anti-inflammatory activity refers to the peptide concentration (0.08-20 μM) 
that significantly reduced TNF-α expression of murine macrophages, 2 hours after co-incubation with 100 ng/ml 
lipopolysaccharide (LPS; E. coli) or 1 μg/ml lipoteichoic acid  (LTA; S. aureus) [147]. If this could not be achieved, >20µM 





1.4.1.2 Cathelicidins: mechanisms of action and therapeutic potential  
The cationic and amphipathic nature of cathelicidins is at the center of their 
bactericidal properties [131, 140, 148–150]. These peptides can elicit a multitude of 
antibacterial mechanisms, however, most can be classified as either 1) damaging the 
bacterial membrane or 2) disrupting essential intracellular processes [131, 140, 148, 151, 
152]. For the former pathway, the high diversity of cathelicidins has led to the creation of 
several models, including the carpet-, toroidal- and barrel-stave models, that each 
illustrate their interaction with the cell membrane in a different way [131]. For example, 
utilizing lipid mixtures that mimic the composition of a bacterial membrane and 
fluorescence spectroscopy, researchers have demonstrated that the pig cathelicidin 
(PMAP-23) likely elicits its antibacterial properties by accumulating on or “carpeting” the 
surface of the membrane [153]. It is speculated that at the core of these different models 
is the electrostatic binding of the cationic cathelicidins to the negatively charged 
phospholipids composing the bacterial membrane [131]. Specifically, this interaction has 
been found to result in the peptides accumulating on or embedding in the cell membrane 
[149, 154–156]. Consequently, this can cause either a detergent-like destruction of the 
membrane, the formation of full cathelicidin-lined channels, or simply create holes in the 
membrane [131, 140, 151, 156]. For example, additional fluorescence microscopy studies 
have shown that the human cathelicidin (LL-37) “carpets” the bacterial membrane of 
Escherichia coli, causing a global destruction of the membrane, yet utilizes a more 
toroidal mechanism to create distinct pores in the membrane of Bacillus subtilis [157, 
158]. Regardless of the exact method, the end result of these interactions with the 
bacterial membrane is usually a loss of membrane integrity and eventually bacterial death 





cathelicidins can enter the cytoplasm from the cell membrane and interact with 
intracellular components, such as RNA, DNA, enzymes, as well as various chaperones 
[140, 152, 156]. One such cathelicidin is indolicidin, a bovine cathelicidin that has been 
found to permeabilize the membrane of E. coli without causing lysis, instead eliciting its 
antimicrobial effects by inhibiting DNA synthesis [164]. The binding of these negatively 
charged intracellular molecules has resulted in cathelicidins preventing aspects of protein 
synthesis, cell division, DNA replication, nucleic acid biosynthesis, and a number of other 
processes essential to bacterial survival [151, 152, 156, 165–169]. Through these two 
main mechanisms, these positively charged peptides have retained antimicrobial activity 
for millions of years [170]. 
It should also be noted that this multi-target approach to bacterial killing, makes 
any single resistance mechanism likely ineffective against cathelicidins [171–174]. 
Further, avoiding cathelicidin-mediated disruption of the bacterial membrane would 
require massive changes to its core elements and would likely come at the cost of normal 
membrane function and structural integrity [140, 151, 173]. Moreover, the strong 
negative charge of the bacterial membrane has been found to cause cathelicidins to 
selectively interact with these microbes over the more neutrally charged eukaryotic cells 
[131, 140, 175]. Together these factors help explain the current efficacy of these peptides 
against AMR bacteria [169, 176–179] and support their potential as the next generation of 
antimicrobial therapeutics [131, 172]. 
Beyond their direct antibacterial effects, cathelicidins have also been shown to 
exhibit a diversity of immune-related functions that may be beneficial for treating lung 
infections [141, 177, 180]. The exact effect, whether pro-inflammatory or anti-





peptide itself. For example, LL-37 and the murine cathelicidin (CRAMP) have both been 
found to skew macrophage polarization towards a more pro-inflammatory phenotype, yet 
also reduce pro-inflammatory cytokine production in these macrophages in the presence 
of bacterial by-products [141]. Additionally, the specific pathways involved in the 
immunomodulatory effects of cathelicidins, require further study. However, they can be 
broadly classified into directly or indirectly affecting chemokine production, apoptosis, or 
chemotaxis of various immune cells, among other mechanisms [141]. Simply put, the 
ability of these peptides to regulate the immune response goes well beyond their ability to 
electrostatically bind negatively charged microbial by-products and prevent toll-like 
receptor (TLR) activation [141, 177, 180]. In fact, in the context of bacterial lung 
infections, even pro-inflammatory effects may be beneficial to help boost the immune 
response and ensure proper elimination of bacteria in the lung. In summation, the wide 
array of immune-related effects elicited by cathelicidins could promote a more balanced 
rather than excessive immune response during infection, in addition to aiding bacterial 
clearance. 
Overall, the therapeutic potential of cathelicidins is quite diverse. For example, 
cathelicidins have been shown to promote wound healing [181, 182], help regulate the 
immune system [141, 177, 180], and combat a wide variety of pathogens, including 
bacteria [155, 160, 172, 183], fungi [184, 185], viruses [186–188], and parasites [189, 
190]. Many of these therapeutic properties could be of significant value for treating 
bacterial pneumonia. However, this thesis will concentrate on the mechanisms of 
bacterial killing and immune modulation through which these ancient peptides can help 
combat AMR infections in the modern day [140, 141, 176, 177, 180, 191–195]. 





peptides have been assessed in clinical trials [196]. Obstacles to development often 
involve either toxicity towards eukaryotic cells (observed at high doses) or the loss of 
activity due to environmental conditions in vivo [79, 180, 196–199]. Thus, to make these 
peptides a clinical reality for pneumonia, preclinical studies are required to address 
pulmonary delivery and toxicity challenges, as well as inhibitory interactions with 
environmental factors. Lastly, the selection of an optimal cathelicidin for surfactant 
delivery requires that the peptide has broad spectrum activity against clinically relevant 
bacteria, such as P. aeruginosa, and resistance to environmental inhibition.  
 
1.4.1.3 Chicken cathelicidin-2 
Based on previous studies, one cathelicidin with properties suggestive of a strong 
therapeutic potential is chicken cathelicidin-2 (CATH-2) [79, 137, 177, 180, 200, 201]. 
Originally called CMAP-27, CATH-2 is a 26 amino acid peptide found almost 
exclusively in immune cells known as heterophils [138, 202]. It is one of four 
cathelicidins identified in chickens and is cleaved into its active form by a serine protease 
[137, 146, 202]. In terms of its antibacterial properties, CATH-2 has shown high efficacy 
against a wide variety of clinically relevant bacteria, including P. aeruginosa and S. 
aureus, independent of their resistance mechanisms to classical antibiotics [79, 137, 146, 
177, 201, 203]. Live imaging studies, utilizing fluorescently labelled versions of CATH-
2, have also characterized its ability to rapidly permeabilize the bacterial membrane and 
enter into the cytoplasm of both Gram-positive and Gram-negative bacteria [152, 156]. In 
addition, in vitro and in vivo experiments have found that bacteria, such as P. aeruginosa, 
do not elicit a pro-inflammatory response when killed by CATH-2, unlike other methods 





dual activity of this peptide for treating bacterial lung infections. Specifically, it has been 
found to not only kill pathogens that target the airways, but also regulate the subsequent 
host immune response [146, 177, 180, 192, 204]. Overall, CATH-2 has been shown to 
have a diverse range of immunomodulatory properties, including its ability to 
downregulate the recruitment of inflammatory cells and production of pro-inflammatory 
chemokines in response to bacterial by-products [177, 192, 204]. This broad-spectrum 
activity against AMR bacteria, in combination with its efficacy for immune regulation, 
make CATH-2 an ideal candidate for treating bacterial lung infections. 
Beyond its potency as an antimicrobial and anti-inflammatory agent, it should also 
be noted that the activity of CATH-2 has been found to be more resistant to 
environmental factors than other peptides. For example, at “high” salt concentrations the 
potent antibacterial effects of many cathelicidins, including LL-37 and CRAMP, have 
been found to be significantly reduced [199]. This salt sensitivity among these peptides 
poses a major obstacle in their development as novel therapeutics for lung infections, as 
similar salt levels are observed in the airways [205–207]. Complicating treatment further, 
many respiratory conditions linked to chronic infections, such as CF are characterized by 
even higher salt concentrations in the airways [205, 208]. In contrast, CATH-2-mediated 
bacterial killing has been shown to be unaffected by “high” salt conditions [137, 146]. 
Additionally, the antibacterial effects of many cathelicidins, like LL-37 and eCATH-1 
(horse) have also been shown to be inhibited by physiological levels of serum proteins 
[180, 197]. However, under serum conditions that resulted in the complete loss of activity 
for these other peptides, the potent bacterial killing of CATH-2 was found to be 
unaffected [180]. This insensitivity to complex environmental factors, could be associated 





unique kink region, created by a proline residue at amino acid position 14 [146]. This 
region has been shown to be essential to the therapeutic properties of CATH-2 and has 
also been used to explain its greater retention of activity when combined with a surfactant 
vehicle, compared to other cathelicidins [79, 146, 177]. Together, its resistance to 
external factors, high potency against AMR bacteria, and various immunomodulatory 
effects, make CATH-2 an ideal candidate for surfactant-based delivery in the treatment of 
pneumonia. 
 
1.4.1.4 Evaluating surfactant-cathelicidin mixtures 
Our research group has previously evaluated surfactant-cathelicidin combinations 
based on the antimicrobial functions of the suspended peptides. For example, bacterial 
killing curves against various lab stains and clinical isolates have been utilized to 
determine surfactant’s effect on the bactericidal properties of these peptides [79, 177]. In 
general, these studies found that combining a cathelicidin with an exogenous surfactant 
significantly inhibited its antibacterial activity [79, 177]. Further, despite their potency 
against AMR bacteria, the antimicrobial effects of all cathelicidins tested, except CATH-
2, were found to be completely abolished when suspended in BLES [79, 177]. Although 
the exact mechanism was not investigated, it was speculated that the reduction in bacterial 
killing was likely related to the cationic nature of these peptides and their ability to 
interact with the negatively charged phospholipids of the exogenous surfactant used [79]. 
This theory has been supported by a subsequent computer modeling study, but not 
directly tested [209]. Thus, a better understanding for the inhibitory mechanism of 
exogenous surfactants on cathelicidins, and the structural characteristics of CATH-2 that 





Additionally, it should be noted that although there has not been any indication that 
surfactant interferes with the anti-inflammatory properties of cathelicidins, there has also 
been a lack of direct in vitro analysis. Specifically, there are no studies that have directly 
compared the anti-inflammatory effects of a cathelicidin suspended in surfactant to the 
peptide alone. In general, studies evaluating the immunomodulatory effects of these 
peptides in combination with surfactant have been limited to overall efficacy in vivo 
[177]. Therefore, better insight into the effects of surfactant on the immunomodulatory 
properties of these peptides is needed. 
Using various biophysical techniques, our research group has also performed studies 
to evaluate the functionality of surfactant in surfactant-cathelicidin mixtures. One such 
study, utilized the Langmuir probe and atomic force microscopy to demonstrate that 
combining cathelicidins with bovine lipid extract surfactant (BLES) enhanced surfactant 
spreading, through their ability to incorporate into the surfactant film [79]. However, in 
the same study, biophysical analysis on a CDS revealed that this incorporation by some 
cathelicidins, including CRAMP and LL-37, interfered with the ability of BLES to 
achieve low surface tensions during cyclic compressions, whereas other peptides, such as 
CATH-2 did not [79]. These findings have been further supported by a recent computer 
modeling study, that utilized molecular dynamic simulations to reveal that antimicrobial 
peptides, including LL-37 and CATH-2, can quickly penetrate the pulmonary surfactant 
film [209]. These biophysical techniques were expanded upon in Chapter 2 to develop a 
new in vitro screening tool for surfactant-based therapeutics, including surfactant-






1.4.2 Acute respiratory distress syndrome 
In addition to bacterial pneumonia, a second respiratory condition that may benefit 
from treatment with a surfactant-based therapeutic is ARDS. As touched on previously 
(see section 1.2.4 Exogenous surfactant therapy), ARDS is defined by the physiological 
criteria of severe lung dysfunction, that most commonly occurs after initiating insults, 
such as sepsis or pneumonia, to the lung [47–49, 210]. The Berlin definition for ARDS 
established specific diagnostic criteria for the syndrome, including a partial pressure of 
oxygen/fraction of inspired oxygen (PaO2/FIO2) ratio of less than 300 mmHg with a 
minimum of 5 cmH20 for positive end-expiratory pressure (PEEP) during mechanical 
ventilation [47–49, 210]. It also created three different categories of ARDS (mild, 
moderate, and severe) based on the severity of a patient’s hypoxemia [47–49, 210]. 
Overall, ARDS is a condition with a 30-50% mortality rate, whose treatment relies 
heavily on mechanical ventilation strategies to improve survival [211–213]. Even before 
the COVID-19 pandemic, it was the most common cause of death in the ICU and a large 
burden on the health care system [210, 214–216]. Furthermore, to combat COVID-19 
related ARDS, many researchers have begun to reconsider direct surfactant therapy and 
its potential as a drug delivery vehicle [62].  
Despite extensive research into the pathophysiological processes affecting the 
initiation, development, and severity of ARDS, targeting these processes by 
pharmacological intervention has been largely unsuccessful [214, 217–220]. Specifically, 
there have been many drugs tested in clinical trials for ARDS that failed to demonstrate a 
significant decrease in mortality, despite strong scientific evidence rationalizing their 





217–220]. These include, among many others, β2 agonist (to reduce edema), heparin (to 
reduce fibrin deposition), antioxidants (to mitigate oxidative stress), exogenous surfactant 
(to restore the surfactant system), and glucocorticoids (to downregulate the overwhelming 
inflammation). Although a variety of aspects may have contributed to the lack of 
pharmacological efficacies observed, drug deposition in the areas required for clinical 
efficacy is certainly one important aspect. For example, many of the ARDS trials 
mentioned utilized aerosolization as a drug delivery technique in which, as mentioned 
above (see section 1.3 Exogenous Surfactant as a Drug Delivery Vehicle), results in drug 
deposition mainly in the central airways rather than the alveoli [214, 217–220]. 
Moreover, drug distribution for inhaled therapeutics is also dependent on airflow. As 
such, inhaled drugs will accumulate mainly in the inflated areas of the lung, whereas the 
pathophysiological processes targeted by the drug occur in areas with edema which does 
not receive airflow. These, as well as the added aspects of overcoming the endogenous 
surfactant impairment and positive outcomes in ongoing clinical trials for surfactant 
therapy, provide a strong rationale for utilizing a surfactant vehicle when testing 
therapeutics for ARDS [62]. 
Further complicating treatment, ARDS is a complex and heterogenous disease, 
whose pathological progression can vary greatly across patients [48, 210, 221–223]. For 
example, ARDS from gastric acid aspiration may start with a chemical injury to the 
epithelium and endothelium, leading to edema and surfactant dysfunction, followed by 
pulmonary inflammation [210, 223–225]. In contrast, COVID-19 related ARDS likely 
begins due to the infection of type II alveolar cell, whereas sepsis-induced ARDS is 
initiated by systemic inflammation [213, 216]. Although the chronological order of these 





the alveoli, in most forms of ARDS (Figure 1.3). Further, regardless of the underlying 
processes or initiating events, it seems that overwhelming and maladaptive inflammation 
in the lung is a main contributor to the disease [48, 221–223, 225, 226]. This dysregulated 
pulmonary inflammation is manifested by inflammatory cell infiltration (predominately 
neutrophils), secretion of proteases, inflammatory mediators, and reactive oxygen species 
[48, 221, 222, 226, 227]. Additionally, this accumulation of activated leukocytes and 
inflammatory mediators can cause damage to the respiratory units of the lung, as well as 
alter the permeability of the alveolar-capillary barrier [223, 228, 229]. This could then 
lead to edema and alterations to the endogenous pulmonary surfactant system, further 
contributing to ARDS development [50, 51, 230]. Therefore, new therapeutic approaches 
that can treat alveolar inflammation in ARDS patients would be of substantial therapeutic 







Figure 1.3. Schematic model of intratracheally administered drugs traveling through the 
airways to arrive at the alveolar surface of a A) healthy or B) ARDS patient. In addition 
to airway collapse prior to reaching the alveoli, the drug will also encounter various 
pathologies at the alveoli of the ARDS patient, such as edema fluid, impaired surfactant 
layer, impaired gas exchange, and inflammation. Inflammation includes neutrophil 







A subclass of corticosteroids, glucocorticoids are found in mammalian species and 
play an important role in many physiologic processes [231, 232]. Endogenously, these 
steroid hormones are derived from cholesterol at the cortex of the adrenal gland and 
regulated by the hypothalamic-pituitary-adrenal axis, in response to physiological stress 
or the natural circadian rhythm [231, 232]. At the cellular level, their effects are mediated 
through their binding with the glucocorticoid receptor (GR), found in the cytoplasm of 
almost all human cells [232, 233]. The GR contains various structural domains important 
for glucocorticoid binding, translocation to the nucleus, and DNA binding [234]. In the 
absence of its “ligand”, it is kept in the cytoplasm as a multiprotein complex, where other 
molecules cover its nuclear translocation regions [235]. As such, the binding of a 
glucocorticoid causes the GR to dissociate from this multiprotein complex and translocate 
into the nucleus of the cell [235, 236]. Once inside the nucleus, the activated 
glucocorticoid receptor functions as a ligand-dependent transcription factor. Functionally, 
glucocorticoids derive their name from their ability to increase serum glucose and as 
such, regulate the metabolism of various macromolecules [231, 232]. However, they have 
also been found to play an essential role in immune modulation, reproduction, water 
homeostasis, general growth, as well as normal cardiovascular and cognitive function 
[231, 232]. Although different glucocorticoids are produced across species, the main 
physiologic glucocorticoid in humans is cortisol [231, 232]. As such, synthetic 
glucocorticoids have been designed to structurally and functionally mimic cortisol [237]. 






1.4.2.2 Glucocorticoids: mechanisms of action and therapeutic potential 
Clinically, the main therapeutic success of glucocorticoids has been in the 
treatment of inflammatory diseases, such as asthma, arthritis, Crohn’s disease, and 
ulcerative colitis (in addition to many others) [82, 237–240]. Specifically, the anti-
inflammatory effects of pharmacologic glucocorticoids are mostly attributable to their 
ability to change the transcription state of genes in immune cells [238]. Briefly, the 
glucocorticoid bound GR can affect gene expression directly, by binding DNA or 
indirectly, through protein-protein interactions with other transcription factors [232, 233, 
236, 238]. For the direct pathway, glucocorticoids can affect transcription by increasing 
or decreasing the accessibility of DNA through chromatin remodeling, epigenetic 
modifications, and the recruitment of coactivator complexes [241–245].For example, it 
has been shown that the binding of this activated receptor to the promoter region of a 
gene can promote [243, 246–248] or downregulate [249, 250] transcription by altering the 
recruitment of transcription proteins, including RNA polymerase. For the indirect 
pathway, glucocorticoids can affect gene expression by interacting with various proteins 
and transcription factors to regulate signaling cascades [232, 243]. For example, 
dexamethasone has been shown to elicit its anti-inflammatory effects by binding NF-kB, 
Activator Protein-1 and Protein S (among others) [251–255]. Specifically, these studies 
found that a therapeutic dose of dexamethasone suppressed the transcription for genes 
encoding pro-inflammatory cytokines, chemokines, cell adhesion molecules, and various 
enzymes involved in the inflammatory response [251–255]. Overall, these effects were 
found to result in fewer leukocytes, such as neutrophils, emigrating into the site of 
inflammation and promoted their clearance [251–255]. This potent efficacy for regulating 





straightforward administration have lead to glucocorticoids becoming one of the most 
prescribed medications in the world for treating inflammation [256–259].  
Unfortunately, these highly effective drugs are not without their adverse side 
effects [260]. Their potential for “off target” exposure is associated with their inherent 
ability to pass through biological membranes and the universal expression of the 
glucocorticoid receptor [232, 233]. Although not an exhaustive list, treatment with 
systemic glucocorticoids has been associated with an increased risk of diabetes mellitus 
[261, 262], serious infection [263–265], fractures [266, 267], and osteoporosis [268]. The 
risk of these adverse effects was also found to increase in a dose and duration dependent 
manner. However, glucocorticoid treatment strategies utilizing more targeted 
administration methods have been demonstrated to increase efficacy and decrease rates of 
adverse effects [82, 269–272]. Due to these advantages, it makes intuitive sense to 
explore methods of direct delivery for glucocorticoids treating respiratory condition such 
as ARDS.  
The rationale for using surfactant-delivered glucocorticoids as a therapy for ARDS 
was outlined, in general, in previous sections (see sections 1.3 Exogenous Surfactant as a 
Drug Delivery Vehicle & 1.4.2 acute respiratory distress syndrome) and includes the need 
for downregulating inflammation in the deeper regions of the lung. Briefly, the severe 
lung dysfunction characterizing ARDS is thought to be a consequence of overwhelming 
inflammation, and the subsequent pulmonary surfactant dysfunction, as well as edema at 
the alveoli [48, 221–223, 225, 226]. Despite this strong rationale for anti-inflammatory 
therapies in ARDS, glucocorticoids are not currently recommended for the disease [273, 
274]. As shown in Table 1.3, this could presumably be due to most clinical trials with 





should be noted, that these studies used suboptimal methods to deliver glucocorticoids. 
For example, the most widely used technique to administer glucocorticoids, systemic 
administration, is affected by hepatic drug metabolism, renal clearance, and off-target 
effects, which would all reduce efficacy [275]. Additionally, direct administration of 
glucocorticoids via aerosol-based strategies has been shown to have limited utility in 
ARDS, as delivery is determined by the airflow and CT-imaging studies in ARDS have 
demonstrated a lack of lung inflation in injured regions [276, 277]. Thus, one 
interpretation of these clinical trials is that the effectiveness of glucocorticoids was 
limited by the lack of drug deposition at the alveoli. Lastly, as mentioned in a previous 
section (see section 1.2.4 Exogenous surfactant therapy), exogenous surfactant therapy 
has also been examined for patients with ARDS [46, 56–62]. Although initial meta-
analyses of this therapy did not show an improvement in mortality, intratracheal 
surfactant administration did improve oxygenation and lung compliance [60, 61]. This 
latter improvement is indicative of its proposed function to reach and recruit collapsed 
areas of the lung, as also demonstrated by animal studies [278–280]. Thus, in theory, 
exogenous surfactant could overcome the delivery-hurdle encountered for glucocorticoids 














(per day)  
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Improvements in lung function and injury score 
Increase in PaO2/FIO2 ratio 
Methylprednisolone  
[282] 




Increase in the number of ventilator-free days during 
the first 28 days  
Increase in PaO2/FiO2 ratio and lung compliance 
during the first 28 days 
Methylprednisolone 
[283] 




Improvements in PEEP, with earlier extubation from 
ventilation after 7 days 
Increase in PaO2/FiO2 ratio after 7 days 
Hydrocortisone  
[284] 




No significant change in ventilator outcomes 
No significant change in PaO2/FiO2 ratio 
Hydrocortisone  
[285] 




No significant change in ventilator outcomes 
Increase in PaO2/FiO2 ratio after 7 days 




Increase in the number of ventilator-free days  
Increase in PaO2/FiO2 ratio at day 10 




Increased number of ventilator-free days 
Budesonide  
[288] 




Reduction of all markers of pulmonary fibrosis 
measured at day 15 
Increase in PaO2/FiO2 ratio after 11 days  
Budesonide 
[289] 
Inhalation 2 mg 60 
Not measured 
(3-Days) 
Increase in PaO2/FiO2 ratio for 1st hour after 
treatment  





1.4.2.3 Glucocorticoids: mechanisms of action and therapeutic potential 
A glucocorticoid that has been studied extensively in combination with exogenous 
surfactants is budesonide [78, 94–96, 290–295]. Budesonide is currently a mainstay 
treatment for respiratory conditions, like asthma [83, 296, 297] and a variety of 
inflammatory bowel conditions [298, 299]. It has also shown some clinical success in 
treating various other obstructive airway diseases [83, 272, 300–302] and in combination 
with formoterol, preventing ARDS development [303]. Additionally, budesonide 
delivered by a surfactant vehicle has had success in clinical trials for BPD [92–95] and in 
various animal models [94, 294, 295]. For example, in a piglet model of meconium 
aspiration, budesonide combined with a porcine derived exogenous surfactant resulted in 
improvements to a variety of inflammation-related outcomes, compared to surfactant or 
budesonide alone [94]. Together, these studies demonstrate the potential for surfactant-
delivered budesonide to be an effective treatment option for the alveolar inflammation 
associated with ARDS.    
Further supporting the potential of this mixture to treat ARDS are the specific 
characteristics of budesonide. A synthetic, nonhalogenated 16,17-acetal steroid molecule, 
budesonide has been found to have a topical anti-inflammatory potency 1000-fold higher 
than the endogenous glucocorticoid, cortisol [304]. In fact, it was originally developed to 
be a better, more selective intrapulmonary therapeutic for asthma [83], with higher local 
activity and lower systemic bioavailability [83, 299, 304, 305]. Its minimal availability in 
circulation and local selectivity for the lung, following inhalation, have been shown to be 
linked to its interaction with lung enzymes and extensive first-pass metabolism [306, 
307]. Moreover, although budesonide is moderately lipophilic, its retention and prolonged 





glucocorticoids [83, 306, 308, 309]. Pharmacokinetic studies performed in vivo found that 
these properties are linked to the rapid esterification of budesonide in the airways, by 
coenzyme A [306–308]. Briefly, as explained by Van Den Brink et al., the subsequent 
fatty acid conjugates of budesonide form intracellular deposits inside lung tissue [306]. 
Then, over an extended period the drug is released through the activity of intracellular 
lipases. Furthermore, being slightly more water soluble than other inhaled glucocorticoids 
budesonide has also been shown to display faster dissolution in bronchial fluid [84, 310]. 
Consequently, this has been found to result in a more rapid uptake of the drug into tissue, 
with minimal removal from various clearance mechanisms in the lung [310]. Lastly, the 
tendency of budesonide to have fewer off-target effects has been attributed to its rapid 
metabolism by hepatic CYP3A enzymes and consequently, shorter systemic half-life [83, 
308, 311, 312]. Specifically, this extensive first-pass metabolism seems to create inactive 
metabolites of budesonide, that are easily excreted [83, 308, 311, 312]. Together, these 
pharmacokinetic features give intratracheally administered budesonide a long duration of 
local therapeutic effects with minimal systemic exposure [83, 313]. Thus, with a 
surfactant delivery strategy, intratracheally administered budesonide could reach the 
peripheral sites of inflammation associated with ARDS and be a long-awaited 
pharmacological treatment for the disease. 
 
1.4.2.4 Evaluating surfactant-glucocorticoid mixtures 
As mentioned in the section above, the impact of glucocorticoids, notably 
budesonide, on the function of various exogenous surfactants has been studied 
extensively. Specifically, in vitro analysis has been used to investigate its incorporation, 





surfactants [78, 290, 291, 293, 314]. For example, utilizing a captive bubble 
surfactometer, budesonide has been shown to have a concentration-dependent effect on 
the biophysical properties of the exogenous surfactant, Survanta, but not BLES [290]. 
The researchers found that high concentrations of budesonide were shown to significantly 
inhibit the surface tension lowering properties of Survanta during compression and 
reduced surfactant film stability [290]. Thus, the authors speculated that there was an 
optimum type of exogenous surfactant and glucocorticoid concentration for this 
interaction to occur without inhibiting the surface tension lowering properties of 
surfactant. In a follow up study, utilizing the low cholesterol surfactant, Curosurf, it was 
found that higher concentrations of budesonide would fluidize the surfactant film, without 
altering the minimum surface tension achieved during compression [291]. Expanding on 
the findings of the former study, the researchers inferred that combining glucocorticoids 
with low cholesterol surfactants, like Curosurf or BLES would allow for larger amounts 
of the drug to be delivered to the lung without compromising the surface activity of the 
surfactant [291]. This theory was also supported by a recent wet bridge study, that utilized 
a fluorescently labeled derivative of glucocorticoids, Beclomethasone Dipropionate to 
evaluate drug transport by Curosurf [78]. When administered alone to the donor well, the 
fluorescence of Beclomethasone Dipropionate was not detectable in the recipient well. 
However, administering the drug with the low cholesterol exogenous surfactant resulted 
in a significantly larger fluorescent signal for the recipient well [78]. From these results, 
the researchers concluded that exogenous surfactant was an effective delivery vehicle for 
corticosteroids, capable of efficiently transporting these drugs over the air–liquid 





exogenous surfactant and the concentration of the suspended glucocorticoid can affect 
their interaction.  
In contrast to the numerous in vitro studies analyzing the effect of glucocorticoids 
on surfactant function, there has yet to be a study exploring the effects of this interaction 
on glucocorticoid function. Moreover, animal studies with surfactant-glucocorticoid 
mixtures have mainly focused on biodistribution within the lung, treating surfactant 
deficiency, and the efficacy of this mixture as a prophylactic treatments for lung 
inflammation [91, 293–295]. For example, a recent animal experiment, using a 
radioactive derivative of the drug, 18F-budesonide, demonstrated that intratracheally 
instilling budesonide with Survanta enhanced its biodistribution within the lung [293]. 
Further supporting this delivery approach for glucocorticoids, a study using a rabbit 
model of meconium aspiration assessed the prophylactic efficacy of Curosurf combined 
with budesonide [294]. The researchers found that prophylactic administration of this 
combination alleviated lung inflammation more effectively than either the drug or 
Curosurf alone [294]. Although these studies illustrate the benefits of exogenous 
surfactants for enhancing the delivery and prophylactic efficacy of glucocorticoids, they 
also highlight that additional experiments are required. The investigation of the anti-
inflammatory effects of a glucocorticoid alone or in combination with surfactant at a 
distal site is explored in Chapter 2. In addition, Chapter 4 assessed the in vivo efficacy 






1.5 Summary, Objectives, and Hypothesis  
The complex branching structure of the airways makes direct delivery of 
therapeutics to peripheral sites of inflammation and infection particularly difficult. This 
delivery challenge has prompted the treatment paradigm for lower respiratory tract 
conditions to move towards systemic dosing regimes. Unfortunately, these systemic 
treatment strategies have been shown to be ineffective for inflammatory conditions like 
ARDS and may even promote AMR among pneumonia patients. Moreover, systemic 
dosing comes with the consequence of adverse side effects, largely avoided by routes of 
direct delivery. Thus, there is an urgent need for novel delivery strategies, like 
exogenous surfactant vehicles, that can promote a more localized drug distribution 
to peripheral sites within the lung. 
The overall objective of this thesis was to create a process for screening, 
designing, and testing exogenous surfactants as delivery vehicles for specific 
intrapulmonary therapeutics. The overall hypothesis was that exogenous surfactant 
delivery would enhance the efficacy of antimicrobial cathelicidins and anti-inflammatory 
glucocorticoids for the treatment of bacterial pneumonia and ARDS, respectively. 
To test this hypothesis, Chapter 2 focused on the full characterization and utility 
of the wet bridge transfer system, as an in vitro screening tool for surfactant-based 
therapeutics. Chapter 3 implemented this system to further investigate the inhibitory 
effects of exogenous surfactant on the antimicrobial cathelicidin function, as well as to 
design a more ideal synthetic surfactant to deliver these peptides. Finally, Chapter 4 
utilized a rat model of lung inflammation in both sexes to explore the therapeutic efficacy 
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Due to the complex branching structure of the lung, drug delivery to both the 
proximal and distal regions of this organ remain a significant barrier for the delivery of 
intrapulmonary therapeutics. Whereas nebulization can be utilized to effectively target 
airways, it has limited utility for drugs that may require deposition to the distal alveolar 
regions of the lung [1, 2]. Furthermore, the distribution of nebulized material is largely 
determined by the flow of the inhaled gases and therefore may not be distributed equally 
among all airways, in particular those that may be diseased. Clinical success for direct 
endotracheal instillation of non-nebulized drugs has also been limited [3, 4], with several 
pre-clinical animal models demonstrating that such delivery is primarily localized to the 
central airways with little peripheral deposition [5–7]. Consequently, the vast majority of 
pulmonary diseases are currently treated with high systemic doses of medications which 
can either lead to suboptimal intrapulmonary efficacy or a high prevalence of systemic 
side effects [8]. For example, conventional treatment of acute bacterial pneumonia, a 
common disease of the peripheral airways, includes the empiric use of oral or intravenous 
antibiotics. Treatment failure for this condition may result from inadequate tissue 
concentrations, discontinuation due to systemic toxicity, or the induction of antibiotic 
resistance due to insufficient killing properties. Thus, alternative strategies for targeted 
pulmonary drug delivery are required.  
One proposed strategy to overcome these challenges is through the use of 
exogenous surfactant as a delivery vehicle, due to its unique biophysical properties. A 





ability to efficiently and rapidly distribute throughout both the proximal and distal 
airways [9]. Additionally, exogenous surfactants represent the current standard of care in 
premature neonates in the setting of absolute or relative surfactant deficiency [10–13]. 
Furthermore, it has been shown in preclinical studies that certain therapeutics combined 
with an exogenous surfactant have a significantly greater pulmonary distribution when 
injected directly into the trachea of animals compared to the distribution of therapy alone 
without a surfactant vehicle [14, 15]. Therefore, exogenous surfactants, like bovine lipid 
extract surfactant (BLES), are promising candidates to facilitate pulmonary drug delivery. 
Despite the theoretical advantages and promising preliminary animal studies, 
surfactant-mediated drug delivery remains underutilized in clinical practice. The in vivo 
data on surfactant as a carrier for agents instilled directly to the lung is limited, with few 
in vitro experiments investigating the interactions between surfactant and drugs [16–20]. 
Moreover, the translation of exogenous surfactant into a multipurpose, clinically used 
drug vehicle is hampered by the current testing methodology in which multiple 
permutations of surfactant and drugs require expensive and laborious animal studies for 
pre-clinical testing [9, 16, 17, 21].  
Based on the above observations, the objective of this study was to develop and 
test an in vitro technique to rapidly assess, screen and optimize surfactant-based therapies 
prior to animal studies. This technique is based on methodology utilized in the study of 
biophysics and consisted of a wet bridge transfer system. In the current study we utilize 
this system to characterize surfactant spreading at different concentrations, volumes, and 
temperature, as well as examining the effectiveness of surfactant as a carrier for 






2.2 Materials and Methods: 
Reagents: 
Pseudomonas aeruginosa (P. aeruginosa) ATCC 27853 (ATCC, Manassas, VA, 
USA) was obtained from Sigma-Aldrich. gentamicin, colistin, and ciprofloxacin solutions 
were all obtained from Sigma-Aldrich. Budesonide 0.5 mg/ml (AstraZeneca Södertälje, 
Sweden) is a commercially available clinical preparation suspended in deionized water. 
BLES 27 mg/ml phospholipid concentration (BLES Biochemicals, London, ON, Canada) 
is a commercially available clinical surfactant preparation, stored in 1.5 mM calcium 
chloride and 100 mM sodium chloride. Chicken cathelicidin CATH-2 was synthesized by 
Fmoc (9-fluorenylmethoxy carbonyl) solid-phase synthesis chemistry. The peptide was 
purified to a minimum purity of 95% by reverse phase high-performance liquid 
chromatography prior to biological testing. The peptide was then suspended in non-
buffered sterile saline. For experimental use BLES was re-suspended in sterile saline to a 
phospholipid concentration of 10 mg/ml, with 100 µM CATH-2, 50 µg/ml budesonide, 
100 µg/ml gentamicin, 100 µg/ml colistin, or 100 µg/ml ciprofloxacin.  
 
The Wet Bridge Approach:  
The Wet Bridge Transfer System, schematically shown in Figure 2.1A, consisted 
of a Teflon block with two 20mm diameter wells, a delivery well (Dish 1, D1) and a 
remote well (Dish 2, D2). Each well has a depth of 1mm and was separated by a 0.2mm 
high raised Teflon bridge. To measure surfactant mediated transfer, each well was filled 
with 1 mL 150mM NaCl, 1.5mM CaCl2, and 5mM Hepes (pH 7.4) solution. Then a 





wetted piece of ashless filter paper placed over the Teflon bridge (Figure 2.1A). In this 
system, therapeutics or other compounds can be injected into the delivery well, with 
subsequent measurements of transfer in the remote well. The principle of the 
methodology is that surfactant injected into the delivery well will be able to adsorb to the 
air-liquid interface, and through its spreading capabilities, transfer over the wet bridge to 
the remote well (Figure 2.1B). In contrast, drugs administered to the delivery well that are 
not able to adsorb to the surface or spread across the wet bridge will therefore remain in 
delivery well (Figure. 2.1C). If, however the drugs are mixed with surfactant they will 
then be carried by the surfactant to the surface of the delivery well and transported over 
the wet bridge to the remote well (Figure 2.1D).  
 Unless otherwise noted, our experiments were performed at room temperature 
(24°C) using 200 µL of BLES (10 mg/ml) combined with various drugs/compounds: 
colistin (100 µg/ml), gentamicin (100 µg/ml), ciprofloxacin (100 µg/ml), CATH-2 (100 
µM), or budesonide (50 µg/ml). To assess the effect of temperature, the wet bridge 
system was either put into a cold chamber (4°C), kept at room temperature, or placed into 







Figure 2.1. Schematic representation of the A) Wet Bridge Transfer System when a B) 
surfactant, C) drug, or D) surfactant/drug mixture is administered to the delivery dish. 
 
Functional outcomes on the Wet Bridge: Spreading:  
Surface tension measurement using the Langmuir probe and FilmWare 2.51 
software of the Langmuir balance was used to assess spreading of surfactant. The 
Langmuir probe was dipped into the surface of D1 or D2 to monitor surface tension. The 
surfactant samples were then administered to the delivery well and surface tension was 
recorded over the subsequent 480 seconds.  
 
Functional outcomes on the Wet Bridge: Bacterial Killing: 
For bactericidal and anti-inflammatory experiments an overnight culture of P. 
aeruginosa ATCC 27853 was grown in tryptic soy broth (TSB). Using measurements of 
optical density (OD), 2x106 colony forming units (CFU) of bacteria were then either 
stored in saline or seeded to the remote dish of the Wet Bridge Transfer system. Both the 





antibiotics with or without surfactant were administered to the surface of the delivery 
dish. Eight minutes after administration the wetted piece of filter paper was removed 
using tweezers and all fluid was collected from both dishes and incubated at 37°C for 1 
hour. Then 50 µL of each sample from the remote dish was diluted with 50 µL of saline 
in a polypropylene coated 96-well plate and subsequently diluted 10-10 000-fold. CFU/ml 
was determined by spot plating 10 µL of each dilution in triplicate on tryptic soy agar 
(TSA) plates. These plates were incubated overnight at 37°C and colonies were counted 
to a detection limit of 102 CFU/ml. Samples from the delivery dish were also spot plated 
on TSA plates and incubated overnight at 37°C to ensure no bacterial transfer. 
 
Functional outcomes on the Wet Bridge: Anti-inflammatory analysis:  
RAW 264.7 murine macrophages were a kind gift from Wei-Yang Lu (Robarts 
Research Institute, Western University, Canada). Cells were cultured in “complete growth 
media” consisting of Dulbecco modified eagle medium (DMEM) supplemented with 10% 
Fetal Bovine Serum (FBS) and 5% Penicillin/Streptomycin. Cells were seeded in 12-well 
plates (3x106 cells/well) and allowed to grow to confluence overnight. They were 
stimulated with 2x106 CFU/ml of heat-killed bacteria (90°C for 10 minutes) from the 
overnight culture for 15 minutes prior to the administration of treatments. The ashless 
filter paper was wetted with complete growth media and placed over the Teflon bridge 
before the delivery dish and remote dish were filled with 1mL of complete growth media. 
Then 200 µL of the CATH-2 or budesonide treatments were administered to the delivery 
dish with or without BLES. Eight minutes after this administration the filter paper wet 
bridge was removed with tweezers. Fluid from both dishes was collected and 





for 4 hours at 37°C and 5% CO2. IL-6 levels were measured using an enzyme-linked 




The effect of different phospholipid concentrations on the surface tension 
reducing properties of BLES was calculated using a two-way measure of analysis of 
variance (ANOVA), followed by a Tukey-Kramer post hoc test using saline in Dish 1 or 
Dish 2 as the control group. The influence of different volumes of administration and 
temperature conditions as well as different therapeutics on surfactant spreading and 
surface tension lowering properties were calculated using a one-way ANOVA, followed 
by a Tukey-Kramer post hoc test using BLES at room temperature as the control group. 
The efficacy of the surfactant/drug mixtures at the remote well was calculated by 
analyzing CFU/ml or IL-6 content using a one-way ANOVA, followed by a Tukey-
Kramer post hoc test, and using saline or BLES in Dish 2 as control groups. GraphPad 
Prism 6 was used to graph and analyze data with a minimum of three independent 
experiments per group. Means are reported + the standard deviation (SD), and values 
were considered significantly different at a probability value (P) of less than 0.05. 
 
2.3 Results  
Spreading/Surface Tension:  
Initial experiments characterized surfactant spreading on the wet bridge system by 





surface tension using a Langmuir probe in either D1 or D2. Figure 2.2AB shows the 
change in surface tension over time in D1 and D2 following the administration of 
surfactant to D1. For the first 30 seconds following the administration of surfactant the 
surface tension in D1 and D2 showed an exponential drop in surface tension for 
concentration greater than 1 mg/ml. Higher surfactant concentrations showed a further 
decrease in surface tension during this initial period, but similar linear reductions in 
surface tension during the remaining 7 minutes for both dishes. Quantification and 
statistical comparisons of the minimum surface tension achieved during the 8 minutes 
following administration is shown in Figure 2.2C. The data shows that all concentrations 
of BLES achieved a significantly lower minimum surface tension compared to the saline 
control in D1 and D2. Moreover, higher phospholipid concentrations of BLES achieved 
significantly lower minimum surface tensions than the lower phospholipid concentrations 






Figure 2.2. Change in surface tension of A) Dish 1 and B) Dish 2 following administration of BLES to the surface of Dish 1. 
Arrow indicates time of surfactant administration. C) Minimum surface tension achieved in Dish 1 and Dish 2 over the 480-
second period following surfactant administration. Statistical differences were determined by two-way ANOVA with Tukey-





To assess the effect of delivery volume, an experiment was performed in which 
equal amounts of surfactant were delivered in different volumes to D1. The data shown 
by Figure 2.3 illustrates that the minimum surface tension achieved in D1 or D2 
following the injection of the different volumes was similar among the groups.  
 
Figure 2.3. Minimum surface tension achieved over the 480-second period following the 
administration of different volumes of surfactant with equivalent phospholipid content to 
Dish 1. Statistical differences were determined using a one-way ANOVA with Tukey-
Kramer post hoc test. * p<0.05. Error bars = SD, n=3. 
 
To further characterize the wet bridge transfer system, the effect of three different 
temperatures on the minimum surface tension achieved in D1 or D2 was tested using 
various doses of BLES. Administration of surfactant at room temperature achieved 
significantly lower minimum surface tensions in D1 compared to the low temperature (ice 





Instilling surfactant at room temperature achieved a significantly lower minimum surface 
tension in D2 at surfactant concentrations of 1, 5, 10 and 20 mg/ml compared to the low 
temperature condition (Figure 2.4B). Moreover, administering surfactant at the body 
temperature (infant incubator) condition resulted in significantly lower minimum surface 
tension readings compared to room temperature at surfactant concentrations of 1, 5, and 
10 mg/ml for D1 (Figure 2.4A) as well as 1, 5, 10, and 20 mg/ml for D2 (Figure 2.4B). 
The minimum surface tension achieved under the body temperature condition was 
significantly lower across both dishes for all concentrations of surfactant compared to the 






Figure 2.4. Minimum surface tension achieved under low, room, and body temperature conditions in (A) Dish 1 and (B) Dish 
2 over the 480 second period following surfactant administration. Statistical differences were determined using a one-way 





Proof of principle experiment 1: Surfactant with Antibiotics:  
To assess the influence of different antibiotics on surfactant spreading, the 
minimum surface tension was calculated for each surfactant/antibiotic mixture in D2 over 
the 8 minutes following administration to D1 and compared to the saline and BLES 
controls. All surfactant/antibiotic preparations achieved significantly lower minimum 
surface tensions compared to the saline control, but not significantly higher than 
surfactant alone (Figure 2.5). Notably, the addition of colistin to BLES resulted in a 
significantly lower minimum surface tension compared to the BLES control.   
 
Figure 2.5. Minimum surface tension achieved in Dish 1 and Dish 2 over the 480-second 
period following surfactant/antibiotic administration. Statistical differences were 
determined using a one-way ANOVA with Tukey-Kramer post hoc test. * p<0.05. Error 








 To characterize bacterial killing at a distal site, antibiotics were administered 
alone (solid bar) or in combination with BLES (dashed bar) to D1, and a colony counting 
assay was performed in D2. Figure 2.6 shows that none of the antibiotics administered 
alone to the delivery dish had any significant effects on the bacterial growth in D2 
compared to either saline or BLES controls. However, BLES/gentamicin and 
BLES/ciprofloxacin both showed significantly more bacterial killing in D2 compared to 
the controls as well as gentamicin or ciprofloxacin alone (Figure 2.6). In contrast, colistin 
showed no significant change in its bacterial killing when combined with BLES 
compared to the saline, BLES or the antibiotic alone (Figure 2.6). 
 
 
Figure 2.6. Bacterial killing in Dish 2 (2x106 CFU/ml P. aeruginosa) one hour following 
administration of treatment to Dish 1. Statistical differences were determined using a one-







Proof of principle experiment 2: Surfactant with Anti-inflammatory drugs:  
To evaluate the influence of different anti-inflammatory drugs on surfactant 
spreading, the minimum surface tension was calculated for mixtures of surfactant 
combined with either CATH-2 or budesonide in D2 and compared to saline and BLES 
controls. The minimum surface tension achieved in the D2 by BLES/CATH-2 or 
BLES/budesonide was significantly lower than the saline control (Figure 2.7). 
Additionally, the minimum surface tension achieved by BLES/budesonide in D2 was not 
significantly different compared to surfactant alone (Figure 2.7). However, the 
BLES/CATH-2 preparation achieved a significantly lower minimum surface tension 
compared to the BLES control in D2 (Figure 2.7).   
 
 
Figure 2.7. Minimum surface tension achieved in Dish 1 and Dish 2 over the 480-second 
period following surfactant/anti-inflammatory administration. Statistical differences were 
determined using a one-way ANOVA with Tukey-Kramer post hoc test. * p<0.05. Error 





 To assess the ability of an exogenous surfactant to enhance drug delivery, the anti-
inflammatory properties of budesonide or CATH-2 in D2 were determined with either the 
drug being administered alone (solid bars) or in combination with BLES (dashed bars) to 
D1. The positive control signals for this experiment were created by stimulating 
macrophages in D2 with heat-killed bacteria prior to the administration of either saline or 
BLES to D1, creating a large IL-6 signal compared to unstimulated macrophages (red 
dashed line). Furthermore, this data reveals that neither budesonide nor CATH-2 
administered alone to D1 had any significant effect on the IL-6 content of D2 compared 
to the positive controls (Figure 2.8). However, co-administration of BLES with either 
budesonide or CATH-2 into D1 resulted in significantly lower IL-6 concentrations for D2 






Figure 2.8. Anti-inflammatory effects of budesonide or CATH-2 alone or mixed with BLES on stimulated macrophages in 
Dish 2. RAW264.5 macrophages (1x106 cells/ml) were stimulated with 2x106 CFU/ml of heat-killed P. aeruginosa 15 minutes 
prior to administration of treatments to Dish 1. IL-6 content was measured 4 hours following administration of therapeutic 
mixtures into Dish 1. Dashed red line indicates the IL-6 content for unstimulated macrophages. Statistical differences were 






Exogenous surfactant has the potential to be an effective delivery agent for 
pulmonary drugs, however clinical translation remains unfulfilled. The current study 
illustrates the potential use of the wet-bridge transfer system as a tool to screen different 
surfactant/drug preparations based on their ability to spread and elicit therapeutic effects 
at a distal site. Herein, we demonstrate that spreading within this system was shown to be 
dependent on surfactant concentration and temperature. Furthermore, utilization of the 
system was illustrated using surfactant-antibiotic preparations in which surfactant showed 
differing effects on different antibiotics and anti-inflammatory agents. It was concluded 
that this technique can be utilized as an effective in vitro tool to screen and optimize 
various surfactant-drug therapy strategies prior to in vivo testing.  
The wet bridge transfer system we developed to test surfactant as a carrier of 
various molecules for pulmonary delivery was based on previous descriptions of 
biophysical studies examining surfactant lipid film. For example, the biophysical studies 
performed by Yu & Possmayer (2003) used a transfer system to investigate surfactant 
lipid transfer across an air-liquid interface. Additionally, Hidalgo et al., (2017) modified a 
wet bridge system with a captive bubble surfactometer to determine whether surfactant 
would be able to achieve and sustain low surface tensions when combined with 
corticosteroids prior to compression−expansion cycling. Our study takes advantage of the 
wet bridge system, but rather than solely focusing on biophysical properties, we explored 
the transfer of clinically relevant therapeutics including antibiotics and anti-inflammatory 





The concept of enhancing pulmonary delivery for antibiotics through an 
exogenous surfactant is appealing and has been previously investigated [2–4, 7, 9, 11, 16, 
17, 23, 24]. Our data adds to this information as it illustrated that gentamicin, 
ciprofloxacin, and colistin did not inhibit the spreading capability of surfactant, and only 
gentamicin and ciprofloxacin elicited effects in the secondary dish when combined with 
BLES. Thus, it can be speculated that exogenous surfactant would be a useful pulmonary 
drug delivery vehicle to improve the distribution of these two antibiotic medications to 
the more remote areas of the lung. In contrast, the inhibitory effect that surfactant exerted 
on colistin appears to limit the usefulness of this antibiotic with surfactant, or 
alternatively illustrates the need to further investigate drug-surfactant interactions to 
optimize this combination. 
Secondly, we investigated the use of the wet bridge transfer system to study the 
transfer of anti-inflammatory compounds when combined with exogenous surfactant. 
budesonide was chosen since it is currently being utilized in combination therapy with 
surfactant for clinical use and its interaction with surfactant has been studied from a 
biophysical and biocompatibility perspective [20, 25, 26]. The evidence provided here 
with the wet bridge transfer system suggest that it can be used to further explore the 
efficacy of other exogenous surfactants, and optimal dosing, without extensive animal 
studies.  
One of the key features of drug delivery by surfactant will depend on the nature of 
the interaction between the surfactant and the specific drug being tested. Specifically, it is 
essential that the drug is transported with the surfactant, but that the interaction does not 
inhibit the innate function of either the surfactant or the drug itself. Previous studies have 





dependent on either the lipid solubility of a drug or its ability to bind specific components 
of surfactant, such as the phospholipids or surfactant associated proteins [27]. For 
example, the second of our anti-inflammatory agents, CATH-2, is a positively charged 
peptide which likely interacts with the negatively charged lipids of surfactant. This has 
previously been shown to have a slight inhibitory effect on this peptide when testing its 
other function, the ability to kill bacteria [18, 19]. It is feasible that the wet bridge system 
could be used to develop a surfactant with a different lipid composition to optimize the 
transfer and function of the surfactant-CATH-2 preparation. 
Overall, our system for assessing surfactant as a carrier has several advantages 
and potential usages. For example, any other drug that requires delivery to the distal 
alveolar regions of the lung may be suitable for testing on this system, such as 
combination of surfactant with drugs for pulmonary fibrosis, pulmonary hypertension or 
primary lung cancers may have some therapeutic potential. In addition, delivery of other 
compounds, like contrast agents for imaging studies, could also be investigated. 
Furthermore, whereas our studies were performed using a sterile wet bridge and delivery 
dish, other relevant in vivo conditions could be easily incorporated in this proposed set up. 
Inclusion of serum proteins, to mimic edema, or proteases and lipases, to mimic 
inflammatory environments, may be utilized to provide further insight into the properties, 
interaction, and efficacy of surfactant drug combinations. 
Despite the advantages of our proposed methodology, several limitations exist 
which may be relevant. For example, one limitation of the technique is that the volume 
and surface area of the two dishes does not reflect that of the extremely thin hypo-phase 
of the lung. This requires therapeutics within our experimental setup to cross a much 





bacteria or macrophages. It would be possible, however, to build wet bridge transfer 
systems with different size and depth for the delivery dish. The system is also limited by 
the non-alveolar macrophages used in experimentation and the very simplified 
unbranching path from “D1 to D2”.  However, these limitations could easily be overcome 
through the harvesting of alveolar macrophages from bronchoalveolar lavage (BAL) and 
the construction of a wet bridge transfer system with multiple secondary dishes branching 
from the delivery dish. It is also feasible to use the wet bridge and simply collect the 
transferred surfactant-drug combination for further analysis of the experimental system. 
Preliminary experiments for the current study were performed in this fashion and 
provided a confirmatory series of experiments for the antimicrobial and anti-
inflammatory effects. The collection of transferred material in these experiments may also 
allow for future compositional assessment. A second, more substantial limitation is that 
the in vivo environment is much more complex than those environments tested with our 
wet bridge. The wet bridge system detects the ability of surfactant to spread over a 
relatively short distance whereas in vivo surfactant distribution is affected by more than 
its spreading ability alone. Aspects like gravity, delivery volume, delivery technique, and 
mechanical ventilation strategy (if employed) would all have an impact on the surfactant-
based drug delivery. Certainly, the wet bridge transfer technique cannot eliminate in vivo 
experimentation, however it does offer a relatively inexpensive approach to rapidly screen 
surfactant/drug mixtures prior to animal, and ultimately clinical studies.  
 
Conclusion: 
From the data shown in the current study it can be concluded that the wet bridge 





and efficacy at a remote site. Although, the system will always be limited by its ability to 
imitate the physiological characteristics of an in vivo system, it offers the best method for 
rapidly and accurately assessing surfactant based therapies in vitro [28, 29]. However 
future animal studies are still needed to validate the findings of the wet bridge system and 
to further investigate the distribution patterns and metabolism of these preparations in 
vivo. Exogenous surfactants are promising delivering agents for pulmonary therapeutics 
and are expected to improve drug distribution and drug efficacy for patients with 
peripheral airway diseases. This direct delivery of medications to the airways, offered by 
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Chapter 3: Optimizing Exogenous Surfactant as a 
Pulmonary Delivery Vehicle for Chicken Cathelicidin-2  
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The increasing incidence of antimicrobial resistance (AMR) in bacterial 
pneumonia has instigated a much-needed search for new therapeutic approaches for these 
types of infections [1, 2]. One approach, involving the utilization of exogenous surfactant 
for the delivery of antimicrobial peptides (AMPs) to the infected lungs is supported by a 
strong theoretical foundation [3, 4]. The AMPs, such as the chicken cathelicidin, CATH-
2, can target a wide spectrum of antibiotic resistant bacteria, making them potential novel 
therapeutics for bacterial pneumonia, which can be delivered to the areas of infection by 
exogenous surfactant [3, 5–7]. Unfortunately, simply mixing CATH-2 or other AMPs 
with a commercial exogenous surfactant has been shown to impact a drug’s therapeutic 
efficacy [5, 8]. For example, we recently demonstrated that an exogenous surfactant with 
CATH-2 exhibited antimicrobial activity against antibiotic-resistant bacterial isolates 
from cystic fibrosis patients, albeit with less efficacy than CATH-2 by itself [5]. 
Therefore, in order to improve this promising approach, it is important to understand how 
surfactant interferes with cathelicidin function and investigate strategies to minimize this 
interaction, while maintaining the benefits of surfactant delivery.  
 The primary benefit of utilizing CATH-2, and other cathelicidins, for therapeutic 
purposes is their diverse range of pathways to kill bacteria, since their positive charge 
allows them to interact directly with both the negatively charged lipids of the bacterial 
cell wall as well as intracellular targets such as DNA or RNA [9–12]. This multi-target 
approach to killing bacteria has been demonstrated to be effective against a wide 
spectrum of antibiotic-resistant organisms [5–7]. Unfortunately, the use of AMPs to treat 





deliver these peptides to the peripheral sites of infection [13–15]. Therefore, improving 
the pulmonary delivery of these highly effective antimicrobial agents with an exogenous 
surfactant would have substantial therapeutic value.  
 The goal of using exogenous surfactant for drug delivery is to open up collapsed 
airways and areas with edema, in order for the therapeutic to reach the areas of the lung 
affected by infection [16, 17]. Most commercially used exogenous surfactants are derived 
from animal lungs and are complex mixtures of phospholipids (85%), neutral lipids (5-
8%) and specialized surfactant proteins, designated SP-B and SP-C (7-10%) [17–19]. 
Although variations exist among different products, the main lipid components of these 
exogenous surfactants are saturated (dipalmitoylphosphatidylcholine; DPPC, approx. 
40%), unsaturated phosphatidylcholine (PC; approx. 35%), the negatively charged 
phosphatidylglycerol (PG; approx. 10%), and neutral lipids like cholesterol (5-8%) [3]. 
These lipids, together with SP-B and SP-C are ultimately responsible for the ability of 
exogenous surfactant to rapidly adsorb to the air-liquid interface and spread throughout 
the airways [18, 20, 21].  
Together, the above information on surfactant composition and cathelicidin 
properties indicates that CATH-2 may interact with the negatively charged phospholipids 
within surfactant. However, this has not been demonstrated directly, nor is there evidence 
that this interaction interferes with cathelicidin function or if this interaction is crucial for 
surfactant’s ability to act as a carrier for cathelicidins. It is hypothesized that the PG 
component of surfactant inhibits CATH-2 function and that an exogenous surfactant, with 






3.2 Materials and Methods 
Preparations:  
The chicken cathelicidin, CATH-2 was synthesized and purified as described 
previously [22]. It is comprised of 26 amino acids – 
RFGRFLRKIRRFRPKVTITIQGSARF-NH2 and has a positive charge of +9 [23]. The 
commercially available surfactant, bovine lipid extract surfactant (BLES) was generously 
provided by BLES Biochemicals (London, ON, Canada). BLES was stored in 100 mM 
sodium chloride and 1.5 mM calcium chloride with a phospholipid concentration of 27 
mg/mL. Lipid enriched preparations of BLES were created through sonication at 37°C for 
2 hours. The addition of 11.6 mg or 27 mg of individual lipids (DPPC, POPC, or POPG) 
per mL of BLES created 30% or 50% lipid enriched versions of BLES respectively. The 
SP-C peptoid protein mimic (mono-SP-C) utilized in the synthetic surfactants was 
synthesized and purified (>97%) according to previously published protocols [24]. The 
lipid and peptoid compositions of the synthetic surfactant preparations are summarized in 
Table 3.1. All BLES preparations, lipid mixtures, and synthetic surfactants were used at 
10 mg/mL phospholipid. 
  
Bacterial killing curves: 
Bacterial killing curves were performed as previously reported [5]. Briefly, an 
overnight culture of Pseudomonas aeruginosa (P. aeruginosa; ATCC 27853), obtained 
from Sigma-Aldrich (Oakville, ON, Canada), was grown in tryptic soy broth. Using 
measurements of optical density, 2×106 colony forming units (CFU) of bacteria were 





with either saline (No Lipids), BLES, individual lipid components at 1–2 mg/mL 
phospholipid, lipid enriched BLES or a synthetic surfactant. These mixtures were then 
incubated with the bacteria for 3 hours at 37°C before being serially diluted 10–10 000-
fold, with 10 µl of each dilution being spot plated in triplicate on tryptic soy agar (TSA) 
plates. The plates were then incubated at 37°C overnight and counted the following 
morning. No bacterial growth was designated as a bacterial concentration of less than 100 
CFU/mL. 
 
Isothermal titration calorimetry (ITC): 
For ITC analysis, vesicles of POPC and POPG were generated using the extrusion 
technique as previously reported [25]. Phospholipid content was determined as inorganic 
phosphate after treatment with perchloric acid by UV-VIS spectroscopy[26]. POPC and 
10%POPG/90% POPC vesicles were diluted to 1.5 mg/mL, while POPG vesicles were 
further diluted to 0.15 mg/mL. For measurements using BLES, the stock solution was 
diluted to 1.5 mg/mL. Interactions between CATH-2 and large unilamellar vesicles 
consisting of POPC and/or POPG, or between CATH-2 and BLES were tested using ITC. 
All ITC experiments were performed on a Low Volume NanoITC (TA instruments - 
Waters LLC, New Castle, USA). In each experiment, the ITC cell chamber was filled 
with 190 µl of vesicles or BLES, and the syringe was filled with a 50 µl solution of 320 
µM CATH-2. Titrations were incremental with 2 µl injections at 300 seconds intervals. 
Experiments were performed at 37°C and data were analyzed with the Nano Analyze 








Solid-State nuclear magnetic resonance (ssNMR) spectroscopy: 
For ssNMR, DOPG unilamellar vesicles were prepared with 5 mM HEPES pH 7.5 
and 50 mM NaCl by the extrusion technique and using filters with a 0.2 µm cut off[27]. 
Phospholipid concentration was determined as inorganic phosphate after treatment with 
perchloric acid[28]. CATH-2 was added to DOPG vesicles to a final molar ratio of 1:50 
CATH-2/DOPG. The interactions between CATH-2 and unilamellar vesicles of DOPG 
were assessed using ssNMR. Vesicles were collected after ultracentrifugation and were 
spun in 3.2 mm rotors. Static 31P ssNMR spectra were acquired at 500 MHz magnetic 
field (1H-frequency) and a sample temperature of 295 K. Heteronuclear proton 
decoupling did not affect the spectra and was switched off for all measurements. The 
resulting 31P powder pattern was apodised with 50 Hz exponential line-broadening and 
baseline corrected. 
 
Bacterial killing and surface tension measurements on the wet bridge transfer system  
To analyze surfactant spreading and bactericidal properties, the wet bridge 
transfer system was set up as previously described[29]. The system consisted of a Teflon 
block with two 20 mm diameter wells, a delivery well, and a remote well. Each well has a 
depth of 1 mm and was separated by a 0.2 mm high raised Teflon bridge. A wetted piece 
of ashless filter paper was placed over the Teflon bridge to join the delivery and remote 
wells. Both wells were then filled with 1 mL of a 150 mM NaCl, 1.5 mM CaCl2, and 5 
mM HEPES (pH 7.4) solution. To determine surfactant spreading, preparations were 
administered into the delivery well and surface tension was measured in the remote well 





a period of 480-seconds after 200 µL of surfactant preparations or saline was 
administered to the delivery well.  
For bacterial killing experiments with the lipid enriched versions of BLES, the 
overnight culture of P. aeruginosa was serially diluted to 2×105 CFU and seeded to the 
remote well. Then 200 µL of cathelicidins (0-100µM) were administered to the surface of 
the delivery well with saline, BLES or 30% lipid enriched BLES preparations. For 
bacterial killing experiments with the synthetic surfactant preparations, the wet bridge 
transfer system was modified through the addition of a lower sucrose layer. Both wells 
were filled with 800 µL of a 10% sucrose solution (150 mM NaCl, 1.5 mM CaCl2, 5 mM 
HEPES). Then 100 µL of the same solution without sucrose was added to make a thin 
upper layer on top of the sucrose layer. For these experiments the overnight culture of P. 
aeruginosa was serially diluted to 2×106 CFU of bacteria and seeded to the remote well 
above the sucrose layer. For treatments, 100 µL of either saline, BLES or synthetic 
surfactants with or without CATH-2 (100 µM) were administered to the surface of the 
delivery well. Eight minutes after administration the wetted piece of filter paper was 
removed, and all fluid was collected from both dishes to be incubated at 37°C for 3 hours. 
Then 50 µL of each sample from the remote well was diluted with 50 µL of saline in a 
polypropylene coated 96-well plate and subsequently diluted 10–10,000-fold. CFU/mL 
was determined by spot plating 10 µL of each dilution in triplicate on TSA plates. These 
plates were incubated overnight at 37°C and colonies were counted to a detection limit of 
100 CFU/mL. Samples from the delivery dish were also spot plated on TSA plates and 








All data points shown represent the average of at least three independent 
repetitions. Statistical significance was determined by two-way analysis of variance and 
one-way analysis of variance (ANOVA) followed by a Tukey-Kramer post hoc test to 
determine differences among experimental groups. Results are presented as mean ± the 






Table 3.1. Lipid and peptoid compositions for synthetic surfactants. 













20% POPG 35 40 20 5 2 
10% POPG 35 50 10 5 2 
5% POPG 35 55 5 5 2 
2.5% POPG 35 57.5 2.5 5 2 
0% POPG 35 60 0 5 2 






Bacterial killing curves: 
To investigate how exogenous surfactant and its lipid components affect 
antimicrobial peptide function, bacterial killing curves were performed with CATH-2 
combined with 10 mg/mL BLES or 1–2 mg/mL of individual surfactant lipids (Figure 
3.1). Shown on each of the panels (Figure 3.1A–D) for comparison purposes, CATH-2 
combined with saline (no lipids) exhibited potent bactericidal activity against P. 
aeruginosa, reducing bacterial growth below detectable limits at 5 to 10 μM. In the 
presence of 10 mg/mL BLES, the antimicrobial properties of CATH-2 were significantly 
reduced at concentrations of 5 μM or greater (Figure 3.1A). Since BLES contains 
approximately 10% PG, CATH-2 mediated killing was tested in the presence of 1 mg/mL 
POPG. Similar to BLES, the presence of POPG at 1 mg/mL phospholipid significantly 
reduced CATH-2 killing at concentrations of 5 μM or greater compared to the peptide 
combined with no lipids (Figure 3.1B). Additionally, mixing CATH-2 with 2 mg/mL 
POPG resulted in a complete loss of its bactericidal properties. In contrast to the effect of 
POPG, there was no significant difference in the bacterial killing of CATH-2 combined 
with DPPC or POPC at 1–2 mg/mL phospholipid, compared to the peptide with no lipids 
(Figure 3.1CD). To explore if the PG effect was specific to CATH-2, killing curves for 
CRAMP, PMAP-23 and LL-37 were also performed in the presence of BLES or 
individual surfactant lipids. All three peptides showed complete inhibition of their 






Figure 3.1. Killing curves for CATH-2 combined with BLES or individual surfactant lipids. Shown are the bacterial killing 
curves for CATH-2 suspended in either A) BLES, B) POPG, C) POPC, D) DPPC or no lipids (saline). Colonies were counted 






Figure 3.2. Bacterial killing for AMPs combined with individual surfactant lipids. Shown are the bacterial killing curves for A) 





P. aeruginosa. Error bars = SD; n=3. Porcine PMAP-23, human LL-37 and mouse 
CRAMP were all synthesized and purified as described previously [22]. Bacterial 
colonies were counted to a detection limit of 100 CFU/ml. When combined with no lipids 
each of the AMPs exhibited potent bactericidal activity. However, in the presence of 
BLES or 1–2 mg/ml POPG the antimicrobial properties of all three cathelicidins were 
completely abolished. There was no difference in the bacterial killing of any of the AMPs 
in the presence of DPPC or POPC at 1–2 mg/mL phospholipid compared to the peptide 
with no lipids. 
 
To determine the effects of modifying an existing surfactant’s lipid composition 
on cathelicidin function, bacterial killing curves were performed for CATH-2 mixed with 
30–50% lipid enriched preparations of BLES (10 mg/mL). Suspension of CATH-2 in 
30% or 50% POPG enriched BLES resulted in a complete loss of the peptide’s 
antimicrobial properties (Figure 3.3A). However, at concentrations of CATH-2 of 5 μM 
or greater, the 30% DPPC and POPC enriched BLES preparations were found to kill 
significantly more bacteria than BLES/CATH-2, resulting in a 2–log reduction in 
bacterial viability at 20 μM (Figure 3.3BC). At those concentrations of CATH-2, 50% 
DPPC or POPC diluted BLES also showed significantly more bacterial killing compared 





Figure 3.3. Antimicrobial activity of CATH-2 in lipid enriched preparations of BLES. 
Displayed are the bacterial killing curves for CATH-2 suspended in 10 mg/mL of 30-50% 
A) POPG, B) POPC, or C) DPPC enriched versions of BLES. Colonies were counted to a 
detection limit of 100 CFU/mL. *p<0.05 for BLES + 30% lipid vs BLES, +p<0.05 for 





ITC and ssNMR of CATH-2 mixed with individual surfactant lipids: 
To further examine the interactions between cathelicidins and exogenous 
surfactant, CATH-2 and large unilamellar vesicles of individual lipids or BLES were 
tested using ITC. As displayed in Figure 3.4A (bottom panel), there was no, or very little 
heat production observed when CATH-2 was injected into the POPC sample, with an 
enthalpy of -3.0 kJ/mol. However, when 10% POPG was added to the vesicles, a large 
increase in heat production was observed following CATH-2 injection, indicative of 
exothermic binding (Figure 3.4A; top panel; ΔH = -13.2 kJ/mol). For both BLES and 
100% POPG vesicles, the binding of CATH-2 resulted in a 3–fold higher release of heat 








Figure 3.4. ITC Binding of CATH-2 to vesicles and BLES. Shown are representative 
thermograms of of ITC experiments with titration of 320 μM CATH-2, into 1.5 mg/mL 








With ssNMR spectroscopy, CATH-2 combined with unilamellar vesicles of 
DOPC and DOPG were assessed by acquiring 31P chemical shift anisotropy powder 
pattern spectra under static conditions. These patterns result solely from the 31P chemical 
shift anisotropy and are sensitive to both the lipid headgroup mobility and orientation[30–
32]. The addition of CATH-2 to the DOPG vesicles resulted in a modest but clear 
broadening of the 31P powder pattern by 1.6 ppm (310 Hz) (Figure 3.5). For BLES the 
addition of CATH-2 caused a broadening of the powder pattern by 2.6 ppm (470 Hz), 
similar as in DOPG, demonstrating peptide-surfactant binding and modulation of the 
surfactant headgroups. Lastly, isotropic signals were not observed for any of the 
measurements, indicating that CATH-2 does not cause very strong curvature to the 
membrane or the formation of spherical micelle-like structures (while curvature effects 







Figure 3.5. ssNMR of CATH-2 mixed with BLES or liposomes. Static 31P solid-state NMR 
spectra acquired at 500 MHz magnetic field. (upper panel) Spectra acquired with 
unilamellar DOPG vesicles in the absence (black lines) or presence of CATH-2 (red lines). 
The span of the powder pattern at approximately 10 % signal height is 42.6 ppm (8610 Hz) 
and 41 ppm (8300 Hz) in the presence and in the absence of CATH-2, respectively. (lower 
panel) Spectra were acquired with BLES surfactant in the absence (black lines) and the 
presence of CATH-2 (magenta lines). The span of the powder pattern at approximately 10 
% signal height is 59.7 ppm (12090 Hz) and 57.1 ppm (11560 Hz) in the presence and in 






Bacterial killing and spreading over the wet bridge for lipid enriched BLES: 
To further examine the effect of PG on CATH-2 responses, BLES preparations 
were enriched with individual lipids to change the relative percentage of PG within the 
preparation. POPC and DPPC at 30 and 50% were utilized to decrease the relative PG 
content, whereas POPG was used to increase the PG content within the BLES 
preparation. Subsequently, the wet bridge transfer system was utilized to investigate if 
CATH-2, suspended in lipid enriched preparations of BLES, delivered at a remote site 
could affect bacterial killing, at a distal site. Suspension in BLES resulted in significantly 
more bacterial killing by CATH-2 (20–100 µM) in the remote well, compared to the 
peptide alone (Figure 3.6). CATH-2 (50–100 µM) suspended in 30% POPC enriched 
BLES resulted in significantly more bacterial killing compared to BLES/CATH-2. When 
mixed with 30% DPPC enriched BLES, CATH-2 (0–100 µM) displayed no change in 
bacterial killing, compared to BLES/CATH-2. Additionally, the suspension of CATH-2 
(50–100 µM) in 30% POPG enriched BLES resulted in significantly less bacterial killing 
at the remote dish compared to BLES+CATH-2. Suspending the other AMPs, CRAMP, 
PMAP-23, or LL-37 at 100 µM with 30% POPC enriched BLES were also shown to 
significantly improve bacterial killing in the remote well compared to BLES/peptide or 






Figure 3.6. Bacterial killing for CATH-2 over the wet bridge transfer system. Presented are the bacterial counts in the remote 
dish (2x105 CFU/mL P. aeruginosa seeded) three hours following the administration of CATH-2, suspended in saline (No lipids), 






Figure 3.7. Bacterial killing for cathelicidins over the wet bridge transfer system. Presented are the bacterial counts in the 
remote well (2x105 CFU/mL P. aeruginosa seeded) three hours following administration to the delivery well of either saline 
(No Lipids), BLES (10 mg/mL) or 30% lipid enriched versions of BLES (10 mg/mL) with or without CRAMP, PMAP-23, or 
LL-37 at 100µM. *p<0.05 vs BLES. Error bars = SD, n=3. When combined with 30% POPC enriched BLES all three peptides 





To examine the spreading characteristics of the 30% lipid enriched preparations of 
BLES, the surface tension in the remote well of the wet bridge was measured over a 480 
second period after instillation into the delivery well. All 30% lipid modified mixtures of 
BLES achieved surface tensions significantly lower than saline (Figure 3.8). However, 
the surface tension achieved by 30% DPPC or POPC diluted BLES were significantly 
higher than BLES alone. 
 
 
Figure 3.8. Surfactant spreading over the wet bridge transfer system for lipid enriched 
BLES. Shown are the surface tensions achieved in the remote dish after the 480-second 
period following administration of saline, BLES (10 mg/mL) or 30% lipid enriched 






Bacterial killing curve for synthetic surfactants: 
To further explore the inhibitory effects of PG and the potential of a PG-free 
surfactant, bacterial killing curves were performed for CATH-2 combined with synthetic 
surfactants of varying PG content. At CATH-2 concentrations of 5 μM and above, 
bacterial killing was found to be significantly greater for synthetic surfactants with 5% or 
less POPG and significantly lower for preparations with 20% POPG compared to BLES 
(Figure 3.9). The synthetic surfactant with a POPG composition of 10% displayed similar 
bactericidal properties to BLES when combined with CATH-2 at 0–20 μM. Lastly, 
combining CATH-2 with PG-free synthetic surfactant (0% POPG) resulted in 









Figure 3.9. Bacterial killing curves for CATH-2 combined with synthetic surfactants. 
Shown are the bacterial killing curves for CATH-2 suspended in saline (No Lipids), 10 
mg/mL of BLES or synthetic surfactant with varying PG content. Colonies were counted 
to a detection limit of 100 CFU/mL. The composition of all synthetic surfactants is 
displayed in Table 1. Error bars = SD; n=3. 
 
Bacterial killing and spreading over the wet bridge for synthetic surfactants: 
To examine the spreading characteristics of the synthetic surfactants, the surface 
tension in the remote well of the wet bridge was measured over a 480 second period after 
instillation into the delivery well. All of the synthetic surfactants tested achieved surface 








Figure 3.10. Spreading over the wet bridge transfer system for synthetic surfactants. 
Shown are the surface tensions achieved in the remote dish after the 480-second period 
following administration of saline, lipids only, BLES (10 mg/mL) or a synthetic 
surfactant preparation to the delivery dish. *p<0.05 vs BLES. Error bars = SD; n=4. 
 
To further evaluate the efficacy of a PG-free synthetic surfactant for delivering 
AMPs to a distal site, CATH-2 (100µM) was administered to the delivery dish of the wet 
bridge transfer system with no lipid, BLES or in combination with a synthetic surfactant. 
Administering CATH-2 with BLES or the 10% PG synthetic surfactant showed similar 
bacterial killing at the remote well (Figure 3.11). CATH-2 suspended in a PG-free 





all other preparations mixed with the peptide. This data implies that the synthetic 
surfactant without PG was capable of spreading over the wet bridge and acting as a 
carrier for CATH-2 to induce killing at a remote location. 
 
 
Figure 3.11. Bacterial killing over the wet bridge for synthetic surfactants/CATH-2. 
Presented are the bacterial counts in the remote dish (2x106 CFU/mL P. aeruginosa 
seeded) three hours following administration to the delivery dish of either saline (No 
lipids), BLES, or synthetic surfactants with or without CATH-2. ap<0.05 vs BLES, 
bp<0.05 vs 10% PG synthetic surfactant, *p<0.05. Error bars = SD; n=9-11. 
 
3.4 Discussion 
The current study tested the hypothesis that the PG component of surfactant 
inhibits CATH-2 function and that an exogenous surfactant with a reduced PG 
composition would increase peptide mediated killing at distal sites. Overall, our results 
supported this hypothesis. Specifically, measurements of bacterial killing as well as both 
assessments of binding indicated that PG interacts with CATH-2, inhibiting its function. 





the ability of CATH-2 to kill bacteria. It was also shown that a PG-free synthetic 
surfactant was capable of carrying CATH-2 to distal sites to kill bacteria. Based on these 
observations it is concluded that synthetic PG-free surfactants will enhance the 
pulmonary delivery of CATH-2 without inhibiting its antimicrobial function. 
Clinically, the relevance of this study is associated with the potential positive 
benefits of treating bacterial lung infections with cathelicidins delivered by a surfactant 
vehicle to reach the deeper areas of the lung. For many pneumonia patients, the 
acquisition of antimicrobial resistant bacteria represents a decisive stage in disease 
progression, towards poor outcomes [34–38]. The ability of CATH-2 and other AMPs to 
target antibiotic resistant bacteria make these molecules interesting for the development 
of novel therapeutics [11, 39, 40]. The ability of exogenous surfactants, to re-open 
collapsed airways and allow antimicrobials access to regions blocked off during the 
infection will also be essential for combating resistance [41–43]. The direct delivery of 
antimicrobials will elevate local therapeutic concentrations at the pulmonary sites of 
infection, improving bacterial clearance and limiting the development of resistance [15, 
44]. Together, CATH-2 and exogenous surfactant represent a desperately needed 
treatment strategy to address the growing threat of multidrug-resistant lung infections. 
An important aspect of the current paper was the utilization of a synthetic PG-free 
surfactant, customized for its ability to maintain CATH-2 activity. Several molecular 
dynamic simulations have suggested that cathelicidins would electrostatically bind the 
anionic lipids in bacterial membranes[45–48]. Similarly, NMR studies have also 
demonstrated that AMPs have a strong tendency to form helical structures that bind 
negatively charged molecules, such as the lipopolysaccharides of Gram negative bacteria 





lysinylation, or changes to the cationic nature of the peptide, have all been shown to alter 
bacterial killing [51–54].  In support of these observations, our ssNMR, ITC and bacterial 
killing data provides strong evidence that PG was the inhibitory component of the 
exogenous surfactant, likely by restricting CATH-2 from directly or indirectly binding 
negatively charged lipids, DNA or other bacterial components [11, 40, 55]. Moreover, the 
enhancement in CATH-2 function following the addition of POPC or DPPC to BLES, 
illustrates the potential benefit for lowering PG content in surfactant to reduce 
electrostatic interactions with these peptides. As such, we generated a PG-free surfactant 
using a surfactant protein mimic of SP-C and demonstrated that such a surfactant, mixed 
with CATH-2, was significantly better at killing bacteria at a remote site compared to PG-
containing surfactants. Since AMPs have been shown to form weak hydrophobic 
interactions with neutral lipid membranes [56–58] it is likely that the PG-free preparation 
transported CATH-2 via these weaker hydrophobic interactions. Importantly, this weaker 
binding likely allowed CATH-2 to still interact with the bacteria at the remote site. Thus, 
we conclude that synthetic PG-free surfactants are optimal delivery vehicles for CATH-2 
and that it is worthwhile investigating such therapeutics in future in vivo studies.    
The generation of a PG-free surfactant for the delivery of CATH-2 also provided 
proof of a more general concept, that synthetic surfactants can be customized for drug 
delivery. The majority of studies exploring surfactant as a carrier of pulmonary antibiotics 
and other pulmonary therapeutics simply mix the drug with a commercial exogenous 
surfactant preparation developed for the treatment of surfactant deficient premature 
infants rather than as a delivery vehicle [3, 16, 29, 41, 59]. Although some success has 
been obtained with these approaches [3], many of the surfactants utilized were animal 





The advantage of a synthetic surfactant is that the specific composition can be optimized 
for the delivery of drugs. We utilized an approach of using surfactant protein mimics, or 
peptoids, since a recent study demonstrated that these peptoid-based surfactant were not 
only active in vivo, but equivalent to animal-derived surfactants for improving 
oxygenation and other physiological outcomes in a model of acute lung injury [60]. 
Peptoids are structurally based on a polypeptide backbone but with side-chains appended 
to nitrogen-backbone, they are highly stable to proteolysis and can be made in high yields 
[24, 61, 62]. Once synthesized, the peptoids can also be easily mixed with a specific lipid 
mixture optimized to spread throughout the lung and for drug delivery, as illustrated in 
vitro with our PG-free surfactant. Overall, we propose that the development of peptoids 
and other synthetic analogs of the hydrophobic surfactant proteins will allow for a more 
mechanistic approach to developing surfactant-based drug delivery approaches.  
Having established the effect of exogenous surfactant on CATH-2, there is also 
therapeutic value in exploring if similar approaches can be utilized for other cathelicidins, 
thereby increasing the clinical arsenal of antimicrobial agents. Unfortunately, the 
presence of exogenous surfactant completely abolished the antimicrobial function of 
many cathelicidins, including human LL-37, mouse CRAMP and pig PMAP-23 [8]. 
However, the current study combined each of these peptides with a lipid enriched 
preparation of surfactant and demonstrated that they could all benefit from delivery by a 
surfactant with a reduced PG content. This ability to create functional exogenous 
surfactants, that minimally interact with a variety of AMPs, will substantially increase the 
treatment options for lung infections. For these reasons, developing exogenous surfactant 
as a delivery vehicle for multiple AMPs, each with their own unique antibacterial 





It should also be noted that there are several limitations to our study. First, the 
bacterial killing was limited to one strain of bacteria. However, it is important to note that 
our previous study showed a similar pattern of inhibition for CATH-2, by surfactant 
against several Cystic Fibrosis derived bacterial strains. As such, we anticipate that PG-
free surfactant with CATH-2 will likely provide improved killing activity against other 
strains as well [5]. Secondly, the PG-free synthetic surfactant was only tested in 
combination with one cathelicidin, CATH-2. However, we did demonstrate that several 
other cathelicidins were also inhibited by PG and benefited from a lipid enriched 
surfactant with a reduced PG composition. From these findings, we predict that LL-37, 
CRAMP, and PMAP-23 would all benefit from delivery by a PG-free synthetic 
surfactant. It should also be noted that high concentrations of AMPs have been associated 
some cytotoxic effects towards mammalian cells, potentially limiting their therapeutic 
potential [8, 63–65]. However, a recent in vivo study showed that co-instillation of 
CATH-2 with an exogenous surfactant was well tolerated, with no deleterious effects up 
to 100 µM [8]. Lastly, our synthetic PG-free surfactant was only designed based on 
minimizing PG content. The preparation contains POPC, DPPC and cholesterol as well as 
a SP-C peptoid, however, this composition could be further optimized with respect to 
these remaining components as well as other surfactant components. 
In conclusion, this paper has demonstrated how exogenous surfactant can be 
designed to be a more effective delivery system for CATH-2. Further, we propose that 
this concept could be applied to other intrapulmonary therapeutics. Direct drug delivery is 
a major hurdle for many pulmonary conditions and designing exogenous surfactants with 
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Chapter 4: Exogenous Surfactant as a Pulmonary 
Delivery Vehicle for Budesonide In Vivo 
A version of this chapter has been published 
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Inflammation is associated with many respiratory conditions, including asthma, 
pneumonia, bronchopulmonary dysplasia (BPD), and Acute respiratory distress syndrome 
(ARDS). However, the effectiveness of anti-inflammatory medications – such as 
glucocorticoids – is location-specific for these conditions in terms of airway (bronchi) or 
airspace (alveolar) involvement [1]. In asthma, for example, inflammation is observed 
primarily in the small airways, which allows for a more direct delivery of therapeutics, as 
evidenced by the effectiveness of standard inhalers [1, 2]. On the other hand, in 
conditions such as ARDS and bacterial pneumonia, inflammation occurs in the more 
distal, alveolar, regions of the lung [1, 3, 4]. Here, the large surface area, and associated 
regions of alveolar edema or airway collapse may contribute to an inability of airway-
delivered therapies to reach distal lung units, to provide effective anti-inflammatory 
functions [1, 3, 4]. In these clinical scenarios, alternative strategies are required to deliver 
therapeutic concentrations of anti-inflammatory medications to these peripheral sites 
within the lung.  
One such approach, is with the use of exogenous surfactant as a delivery vehicle 
for glucocorticoids such as budesonide. Exogenous surfactant is a complex mixture of 
lipids and specialized proteins, usually obtained from natural sources such as cows or pigs 
[5]. The endogenous material, produced by type II alveolar cells in the lung, has been 
well studied and serves a vital biophysical role in reducing surface tension, thereby 
stabilizing the alveoli during normal breathing [6, 7]. The discovery of surfactant 
deficiency in preterm infants led to the development of exogenous surfactant therapy [8]. 





resulted in significant reductions to infant mortality due to prematurity [8, 9]. It is 
suggested that the spreading properties of exogenous surfactant could improve 
glucocorticoid delivery to peripheral sites of inflammation in the lung. In support of this 
notion, exogenous surfactant has already been shown to enhance the delivery of 
glucocorticoids to remote sites using in vitro approaches [10–12]. Additionally, it has 
been shown that through these properties exogenous surfactant can re-open collapsed 
airways, overcome regions of edema, and efficiently spread to the more remote sites of 
inflammation in an injured lung [6]. Together, this data highlights the potential for 
exogenous surfactant to provide locally acting anti-inflammatory drugs access to remote 
regions of the lung otherwise inaccessible to therapeutics. 
When combined with the efficacy of glucocorticoids, the innate biophysical 
properties of surfactant suggest that utilizing exogenous surfactant as a vehicle for 
budesonide would improve its effectiveness for treating remote inflammation in the lung. 
However, this has yet to be demonstrated in vivo. It was therefore hypothesized that 
fortifying an exogenous surfactant with budesonide would enhance efficacy for treating 
pulmonary inflammation in vivo. 
 
4.2 Materials and Methods 
Reagents 
Heat-killed bacteria (HKB) was created from a lab strain of Pseudomonas 
aeruginosa (P. aeruginosa; ATCC 27853), purchased from Sigma-Aldrich (Oakville, ON, 
Canada). Using measurements of optical density, the bacteria was diluted in saline to 3x106 





available preparation of budesonide (0.5 mg/ml), suspended in deionized water, was 
obtained from AstraZeneca (Södertälje, Södermanland, Sweden). Bovine lipid extract 
surfactant (BLES) at 27 mg/ml phospholipid concentration was obtained from BLES 
Biochemicals (London, ON, Canada).  
 
Animal models and treatments 
All animal work was carried out in accordance with guidelines set forth by the 
Western University Council for Animal Care. For breeding, two adult male and seven adult 
female Wistar rats (250 g) were purchased from Charles River (St-Constant, QC, Canada). 
Acclimatization to the animal care facility and breeding were carried out as previously 
described [13]. Once pregnant, rats were housed individually and received standard chow.  
Immediately after birth the litters were culled to 10 pups in order to limit the effect of litter 
size on outcomes.  
To initiate pulmonary inflammation, male or female offspring were weighed, 
anesthetized, and intratracheally instilled with 2 µl of HKB or saline per gram of body 
weight at 25-35 days of age. In animals randomized to a treatment group, this first 
instillation was followed by an instillation of either budesonide (50µg/ml) or 
BLES/budesonide (10mg/ml; 50µg/ml). To minimize the potential effects of any distinct 
litter, only 1 or 2 animals per litter were randomized to any individual experimental group. 
Animals were monitored for 6 hours following instillation, before being euthanized by 
intraperitoneal injection of sodium pentobarbital and exsanguination, by severing the 
descending aorta. After this, a bronchoalveolar lavage (BAL) was performed as previously 
described [14], before the lungs were excised, divided into four pieces and snap frozen in 







Inflammatory cell counts and differential cell analysis of the lavage were done as 
previously described [14]. Briefly, lavage volume was recorded and centrifuged at 150 x g 
for 10 minutes to obtain a cell pellet. This pellet was resuspended and used for cell counting 
and differential analysis to obtain the number of inflammatory cells and neutrophils in the 
BAL. Protein content of the BAL was also measured using a Micro BCA protein assay kit 
from Pierce Biotechnology (Rockford, IL, USA), per manufacturer’s instructions. A 
multiplexed immunoassay kit was utilized per manufacturer’s instruction (R&D Systems, 
Minneapolis, MN) to measure the concentrations of TNF-α, IL-6, MIP-2 and GRO/KC. A 
Bio-Plex 200 readout system was utilized from Bio-Rad (Santa Rosa, CA, USA) and 
cytokine levels (pg/mL) were automatically calculated from standard curves using Bio-
Plex Manager software (v. 4.1.1, Bio-Rad). An aliquot of the 150 x g supernatant was also 
analyzed through a Duck-Chong phosphorous assay as previously described [15]. Briefly, 
the total amount of surfactant in the lavage was determined through the measurement of 
phospholipid-phosphorus [16, 17]. The remainder of the supernatant was then centrifuged 
at 40,000 x g for 15 min to obtain a pellet of the active form of surfactant, the large 
aggregates. This resuspended pellet, as well as its supernatant containing the small 
aggregates, was also analyzed for phospholipid-phosphorus [16, 17].   
 
Frozen lung tissue was utilized for myeloperoxidase (MPO) activity as previously 
described [18]. Briefly, pieces of frozen lung were weighed and then homogenized in 0.02 
M potassium phosphate buffer (pH 6; Sigma-Aldrich) using a PT2100 homogenizer. Lung 





resuspended in 1% hexadecyltrimethylammonium hydroxide detergent solution. This 
mixture was then re-homogenized, before being sonicated at 4ºC and 30% amplitude for 
10 seconds. The resulting preparation was spun at 13,000 x g for 10 minutes at 4ºC. Its 
supernatant was then aliquoted into a 96-well plate at 2 mg/ml and mixed with an MPO 
cocktail containing 3,3',5,5'-tetramethyl-benzidine. Hydrogen peroxide was then added to 
each well and the plate was incubated at 37ºC for 5 minutes. Sulfuric acid was used as a 
stop solution and the plate was read at 450 nm using an iMark plate reader (BioRad). MPO 
activity (units/mg) was calculated from standard curves. 
 
Statistical Analysis: 
All data points shown represent one male or female rat. Statistical significance was 
determined by two-way analysis of variance (ANOVA), followed by a Tukey-Kramer 
post hoc test to determine differences among experimental groups. Results were 
considered statistically significant with a P-value of less than 0.05.  
 
4.3 Results 
Baseline characteristics of the experimental groups are shown in Table 4.1. Prior to 
the first instillation, body weights were found to be similar among the experimental groups. 
There were also no significant differences across groups for protein content in the BAL. 
The phospholipid composition of surfactant, including total surfactant, as well as the large 
aggregate and small aggregate sub-fractions were significantly higher in male and female 
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4.4 ± 0.9 5.1 ± 1.1 
 4.7 ± 
1.2 





*p<0.05 vs saline. 
 
To evaluate the anti-inflammatory effects of delivering budesonide with an 
exogenous surfactant, standard inflammatory markers were analyzed using BAL and 
frozen lung tissue. The instillation of HKB resulted in a significantly higher number of 
inflammatory cells compared to saline (Figure 4.1). The instillation of budesonide, 
following HKB, did not have a significant effect on the number of inflammatory cells as 
compared to the saline or HKB groups. Instillation of BLES/budesonide resulted in 
significantly lower numbers of inflammatory cells compared to HKB and budesonide 





significantly higher number of neutrophils compared to saline, but that both budesonide 
and BLES/budesonide had significantly lower neutrophil counts compared to HKB 
(Figure 4.2A). Additionally, the number of neutrophils was significantly lower in animals 
administered BLES/budesonide compared to those given budesonide alone. The 
instillation of HKB or HKB followed by budesonide also resulted in significantly higher 
MPO activity compared to saline (Figure 4.2B). However, only animals instilled with 
BLES/budesonide had significantly lower MPO activity compared HKB or budesonide 
groups. The instillation of HKB or HKB followed by budesonide was also shown to result 
in significantly higher levels of all pro-inflammatory cytokines tested compared to the 
saline group (Figure 4.3A-D). Compared to animals administered HKB, those receiving a 
second instillation of BLES/budesonide showed significantly lower IL-6 and TNF-α 
concentrations (Figure 4.3A-B). Furthermore, the BLES/budesonide group showed 
significantly lower concentrations of TNF-α and GRO/KC than the budesonide group 
(Figure 4.3B-C). Although the BLES/budesonide group showed lower levels of MIP-2 
and GRO/KC relative to HKB and budesonide groups, the levels were still significantly 





Figure 4.1. The effect of instilling budesonide or BLES/budesonide on the number of 
inflammatory cells in BAL for pediatric rats. Solid circles indicate female rats, open 






Figure 4.2. The effect of instilling budesonide or BLES/budesonide on the A) number of 
neutrophils in the BAL and B) MPO activity in the lung tissue of pediatric rats. Solid 







Figure 4.3. The effect of instilling budesonide or BLES/budesonide on pro-inflammatory cytokine concentrations in the BAL: 
A) IL-6, B) TNF-α, C) GRO/KC, and D) MIP-2. Solid circles indicate female rats, open circles represent male rats. n = 9-12, 





Figure 4.4. The effect of instilling BLES on A) the number of inflammatory cells, and B) 
the number of neutrophils in BAL, as well as C) MPO activity in the lung tissue of 






This chapter tested the hypothesis that fortifying an exogenous surfactant 
preparation, BLES, with budesonide would enhance efficacy for treating pulmonary 
inflammation in vivo. Overall, our results supported this hypothesis. Specifically, BLES 
was shown to enhance the anti-inflammatory effects of budesonide in a rat model of lung 
inflammation by reducing the number of neutrophils, as well as the concentrations of a 
several pro-inflammatory mediators in the BAL. Furthermore, combining budesonide 
with BLES was shown to be beneficial for reducing MPO activity in the lung tissue. It 
should also be noted that these results were displayed across both sexes. Based on these 
observations, it is concluded that utilizing exogenous surfactant as a pulmonary vehicle 
for budesonide enhanced its ability to treat lung inflammation. 
To address our hypothesis, we utilized an in vivo model, where HKB was instilled 
into the lungs of young rats. The rationale for using young rats was practical in nature to 
limit animal usage, as these animals were also utilized for a separate experiment [19]. The 
HKB solution contains a mixture of bacterial components, including lipopolysaccharides, 
that caused a rapid inflammatory response as evidenced by the significant increases in 
neutrophil counts, MPO activity and inflammatory cytokine concentrations as compared 
to animals not receiving HKB. The experimental treatment tested was BLES/budesonide, 
for which intratracheal instillation was confirmed via the increased surfactant levels in the 
BAL fluid following the experiment. It should be noted that our experimental design did 
not include a BLES only treatment. However, an additional experiment with 6 pups 





instillation of HKB (Figure 4.4). Based on these considerations, we deem the 
experimental approach an appropriate test of our hypothesis.  
An important aspect of this chapter was the evaluation of a potential 
glucocorticoid-based treatment strategy in both males and females. Although our 
objective was not to understand the underlying pathways leading to potential sex 
differences, numerous studies have demonstrated the role of sex in patient sensitivity to 
glucocorticoid treatment [20–24]. Unfortunately, these previous studies have also been 
inconsistent with respect to their findings. For example, when developing guides to 
predict responsiveness among asthmatic children, both Wu et al. (2017) and Galant et al. 
(2014) found that the female sex was associated with a higher likelihood of 
responsiveness to inhaled glucocorticoids [20, 21]. On the contrary, some clinical trials 
and epidemiological studies have observed beneficial effects for daily glucocorticoid 
treatment in males, but not females [22, 23]. For the current model of pulmonary 
inflammation, the instillation of HKB was found to result in similar inflammatory 
responses among males and females. Moreover, no sex differences were found for the 
responsiveness of rats to either of the glucocorticoid treatments. Since sex hormones have 
been shown to play such an essential role in inflammatory responses, this lack of 
differences may be related to the young, sexually immature, age of the animals [25]. 
Despite these findings, the extensive role sex hormones play in modulating inflammatory 
pathways combined with the variability shown in human studies suggests that sex must be 
considered when evaluating new glucocorticoid based treatment strategies [26].  
From a clinical standpoint, this chapter builds on previous work in the neonatal 
population. Specifically, it adds to previous clinical studies that explored exogenous 





respiratory conditions like BPD [27, 28]. For example, there are a number of clinical 
trials which have found that administering surfactant multiple times or using it as a 
vehicle for budesonide may reduce the risk of BPD [29, 30]. Similarly, there have been 
clinical trials that have found intratracheal instillations of budesonide, with a surfactant 
vehicle helped to prevent the development of chronic lung disease among preterm infants 
[31]. The current chapter expands these prophylactic approaches in premature lungs, by 
demonstrating anti-inflammatory effects of this treatment strategy, subsequent to the 
pulmonary inflammation.  
To extrapolate our data to the clinical arena, there are a variety of respiratory 
conditions that may benefit from an anti-inflammatory exogenous surfactant; however, its 
potential for treating ARDS is of particular interest. In the first half of 2020, ARDS became 
a well-known syndrome as the critical pulmonary complication resulting from severe acute 
respiratory syndrome coronavirus-2 infections, known as COVID-19. However, even 
before the emergence of COVID-19, ARDS was the most common cause of death in the 
ICU, with no effective pharmacological therapies available [32–35].  Importantly, it has 
been shown that disease severity and progression are directly associated with the 
accumulation of neutrophils into the alveolar space [36, 37], and that many aspects of the 
ARDS pathophysiology, such as edema formation and surfactant dysfunction, are 
consequences of excessive inflammation in the lung [3]. This has provided a strong 
rationale for glucocorticoid-based treatments, as evidenced by numerous clinical trials for 
ARDS and the ongoing trial for COVID-19 [38–40]. Unfortunately, to date, these highly 
effective anti-inflammatory medications have failed to prevent ARDS or show mortality 
benefits [39, 40]. One interpretation of this data is that the efficacy of the glucocorticoids 





exogenous surfactant, as a delivery vehicle, will allow glucocorticoids to become an 
effective treatment option for ARDS. 
It should be noted that there are several limitations to this chapter. First, the 
experiments within this chapter only explored the benefits of one surfactant-
glucocorticoid preparation. The improvements observed for budesonide when 
administered with BLES, suggest therapeutic value in exploring a similar approach for 
other glucocorticoids or anti-inflammatory medications. To this end, our lab intends to 
perform more elaborate in vivo studies with multiple commercially available 
glucocorticoids, like dexamethasone and hydrocortisone, to further explore the benefits of 
surfactant delivery. Secondly, our model of pulmonary inflammation did not imitate the 
edema or airway collapse observed in many respiratory conditions. The current chapter 
did measure protein content in the BAL, however its unchanging level across treatment 
groups suggests that a stronger stimulus is required to disrupt the alveolar-capillary 
barrier. Although there is strong scientific evidence that exogenous surfactant can 
overcome regions of edema and airway collapse, future studies should still evaluate this 
treatment strategy under these inhibitory conditions [41]. 
In conclusion, this chapter demonstrates that the use of exogenous surfactant as a 
delivery vehicle for budesonide can make it more effective for treating lung 
inflammation. Further, we propose that this novel treatment strategy can overcome the 
delivery challenges associated with respiratory conditions like ARDS and treat the 
neutrophilic inflammation underlying the disease. With no effective pharmacological 
options currently available for this condition, direct delivery with exogenous surfactant 
offers an intriguing method for mainstay medications to begin effectively treating this 
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5.1 General Overview 
The objective of this thesis was to develop a process through which exogenous 
surfactants could be designed into more effective vehicles for intrapulmonary 
therapeutics. The challenge of direct drug delivery to the alveoli and adverse 
consequences of the current systemic dosing paradigm in respiratory conditions were the 
rationale for pursuing this novel delivery strategy [1–7]. The hypothesis of this thesis was 
that exogenous surfactant delivery would enhance the efficacy of antimicrobial 
cathelicidins and anti-inflammatory glucocorticoids for the treatment of bacterial 
pneumonia and ARDS, respectively. The specific pursuit of cathelicidins for surfactant-
based delivery was brought on by the high incidence of bacterial pneumonia worldwide, 
rising rates of AMR infections, and lack of new antimicrobials in development [3, 8–16]. 
Similarly, the investigation of glucocorticoid-surfactant mixtures was prompted by the 
long clinical history of effectively treating lung inflammation with glucocorticoids and 
the desperate need for new therapeutics to treat ARDS [17–23]. This final section will 
summarize the major findings of each chapter. It will also explore their overall 
significance to highlight how the chapter fits into the development process for exogenous 
surfactants as drug vehicles, outlined throughout this thesis (Figure 5.1). Lastly, based on 
the literature, and some additional limitations to those discussed in the chapters 








Figure 5.1. Schematic summary of the surfactant-based drug development process 
explored throughout this thesis. 
 
5.2 Summary of Major Findings Chapter 2: The Wet Bridge 
Transfer System  
Chapter 2 began with the development and characterization of the wet bridge 
transfer system as a model system for screening surfactant-based therapeutics. Briefly, 
this in vitro platform utilized two connected wells, in which drugs were instilled into a 
delivery well and function was tested in a remote well, allowing the system to mimic the 
remote areas of the lung where drug activity would be required. The concept behind this 
methodology was that surfactant injected into the delivery well would adsorb to the 





well. The results of this chapter demonstrated that surfactant spreading across the wet 
bridge was dependent on surfactant concentration and temperature, but independent of 
administration volume. The technique was also utilized for screening therapeutics mixed 
with surfactant, specifically antibiotics, by measuring their ability to kill P. aeruginosa 
bacteria in the remote well, as well as anti-inflammatory agents, using stimulated 
macrophages in the remote well and IL-6 concentration as an outcome. The basic idea 
was that a drug combined with surfactant would be detected in the remote dish only if it 
was transported by surfactant. Through these experiments, it was observed that the 
potential efficacy of two antibiotics (gentamicin and ciprofloxacin) as well as two anti-
inflammatory agents (budesonide and CATH-2) benefited from surfactant delivery, 
showing increased efficacy in the remote well compared to the drug alone. Based on these 
findings, it was speculated that exogenous surfactant would be a useful pulmonary drug 
delivery vehicle to improve the distribution of these medications in the lung. In contrast, 
the antibiotic, colistin was not found to benefit from surfactant delivery as it was 
concluded that the inhibitory effects of surfactant on colistin would limit the usefulness of 
this antibiotic. Alternatively, the utilization of this antibiotic with surfactant would 
require further optimization. Together, these findings showcased the wet bridge transfer 
system as a versatile screening tool for surfactant-drug preparations.  
Figure 5.2 shows how these findings fit into the overall experimental paradigm of this 
thesis. Specifically, Chapter 2 highlighted the utility of the wet bridge transfer system as a 
novel in vitro tool for rapidly screening surfactant-based therapeutics, prior to animal 
studies. The technique expanded on currently available in vitro technology, including 
methods for evaluating surfactant biophysics, to allow surfactant-drug mixtures to be 





to spread) and 2) therapeutic function (antibacterial or anti-inflammatory properties) at a 
distal site (Figure 5.2). Thus, this relatively inexpensive in vitro screening tool would 
have the potential to select optimal preparations to test in vivo and therefore reduce the 
number of animal experiments required.  
Beyond the limitations already discussed in Chapter 2, this chapter could be further 
enhanced by a more rigorous biophysical analysis of surfactant-drug mixtures. 
Specifically, other techniques, in addition to the wet bridge, could be utilized to assess the 
effect of a drug on the surface tension lowering properties of an exogenous surfactant 
during expansion/compression cycling [24–26]. For example, future experiments could 
utilize the constrained sessile drop surfactometer (CDS) to further evaluate the effects of 
a drug on surfactant function and design better synthetic surfactants. Through this 
approach, researchers could put the retention of all aspects of surfactant function at the 










Figure 5.2. Schematic summary highlighting how the new methodology of Chapter 2 (the 
wet bridge transfer system) fits into the surfactant-based drug development explored 
throughout this thesis. 
 
5.3 Summary of Major Findings Chapter 3: Surfactant 
Optimization  
Figure 5.3 demonstrates how this data fits into the overall experimental paradigm 
of this thesis. Specifically, the chapter utilized the wet bridge transfer system, in 
combination with other in vitro techniques, to further explore the interactions between 
cathelicidins and exogenous surfactant. The experiments in this chapter expanded upon a 
previous study from our research group, which found that suspending cathelicidins in 
BLES significantly impaired their antibacterial function [3]. The authors speculated that 
the negatively charged PG component of surfactant was inhibiting the function of these 





inhibitory agent within exogenous surfactant and subsequently design a functional, PG-
free synthetic surfactant to increase peptide mediated killing of bacteria at a distal site.  
Although many of the experiments described in Chapter 3 were also performed 
with three additional cathelicidins (LL-37, CRAMP, PMAP-23), optimization was 
concentrated on CATH-2, the cathelicidin previously shown to best retain its 
antimicrobial properties when mixed with BLES [3, 14]. To better understand how 
surfactant lipids interacted with CATH-2 and affected its bactericidal function, isothermal 
titration calorimetry and solid-state nuclear magnetic resonance spectroscopy, as well as 
bacterial killing curves against P. aeruginosa were utilized. The wet bridge transfer 
system was also used to evaluate surfactant spreading and peptide transport (Figure 5.3). 
Investigation of the interactions between individual surfactant lipids and CATH-2 
revealed that PG was the only surfactant lipid to significantly inhibit CATH-2 function, 
showing a stronger electrostatic interaction with the peptide than other lipids. 
Furthermore, when the PG content of an existing surfactant was diluted, through the 
addition of other surfactant lipids, the suspended CATH-2 displayed improved 
antibacterial function. Based on these findings, it was theorized that the electrostatic 
interaction between the negatively charged PG and positively charged peptide was likely 
preventing CATH-2 from binding negatively charged lipids, DNA, or other bacterial 
components. Lastly, although diluting the PG content in an existing surfactant, through 
the addition of other lipids, significantly improved peptide function and distal killing, it 
also reduced surfactant spreading. It was speculated that this loss of surfactant function 
was caused by a dilution of not only PG, but other surfactant components, including SP-B 
and SP-C. To overcome this impairment in surfactant spreading, synthetic mimics for SP-





optimized synthetic surfactant with CATH-2 further improved its delivery and function at 
a remote site. Based on these in vitro experiments, synthetic PG-free surfactants were 
deemed optimal for delivering cathelicidins to the lung.  
 
 
Figure 5.3. Schematic summary highlighting how the wet bridge transfer system and new 
optimization approach of Chapter 3 (synthetic surfactants) fit into the surfactant-based 
drug development explored throughout this thesis. 
 
The findings within this chapter highlighted two important aspects. First, the 
chapter demonstrated of how synthetic surfactants could be designed to retain both 
surfactant and antimicrobial peptide function. Specifically, it showcased how the lipid 
composition of synthetic surfactants could be optimized to overcome their electrostatic 
interactions with CATH-2. As such, the chapter provided proof that synthetic surfactants 
could be customized to deliver a specific therapeutic. Second, the chapter illustrated a 
more mechanistic approach to developing surfactant-based drug vehicles through the use 
synthetic surfactants and various in vitro techniques. Importantly, this approach could 
potentially to be expanded to other therapeutics, improving suspended drug functionality, 





Within the chapter itself, several valid limitations were discussed. However, 
Chapter 3 could have also benefited from a further expansion of its optimization process. 
For example, with the proper insight into the structural characteristics of functional and 
non-functional cathelicidins, the chapter could have benefited from the investigation of 
designer peptides as part of its optimization of surfactant-peptide mixtures [27]. This 
approach would integrate the optimization of the therapeutic, in addition to the surfactant 
vehicle, into the optimization process outlined in this chapter. Further, although Chapter 3 
thoroughly investigated the antibacterial properties of surfactant-cathelicidin mixtures, it 
did not directly evaluate the effects of this interaction on the anti-inflammatory properties 
of these peptides. There have been numerous studies demonstrating the potential of 
cathelicidins as anti-inflammatory agents [28, 29]. Within our own lab, we have shown 
the in vivo efficacy of a cathelicidin-surfactant mixture for reducing lung inflammation 
[14]. However, the direct in vitro analysis of their anti-inflammatory properties alone and 
in combination with an exogenous surfactant has been notably absent in the literature. 
Thus, for cathelicidins delivered by a surfactant vehicle to become viable treatment 
options for pneumonia, it would be recommended that future studies gain a better insight 
into the effect of exogenous surfactants on their immunomodulatory properties.  
 
5.4 Summary of Major Findings Chapter 4: Relevant Animal 
Model  
To expand on the in vitro findings of Chapter 2, this chapter explored the utility of 
a surfactant vehicle for budesonide in vivo. Figure 5.3 demonstrates how utilizing a 





paradigm of this thesis. Specifically, an animal model of pulmonary inflammation was 
created, through an intratracheal instillation of heat-killed P. aeruginosa into the lungs of 
male and female rats. This inflammation was then treated thirty minutes later using a 
second intratracheal instillation of either saline, budesonide, or BLES combined with 
budesonide. The therapeutic efficacy of budesonide compared to surfactant delivered 
budesonide was determined by measuring various markers of inflammation in the BAL 
and lung tissue. Although budesonide exhibited anti-inflammatory effects when 
administered alone for downregulating the number of neutrophils in the BAL, delivery 
with BLES significantly enhanced those effects. Moreover, the BLES/budesonide 
combination was found to significantly lower several other pro-inflammatory mediators 
in the BAL and lung tissue compared to the drug alone. With these results being shown 
across both sexes, it was concluded that utilizing exogenous surfactant to deliver 
budesonide made it more effective for treating lung inflammation.  
Chapter 4 has several significant findings as well as limitations. However, its 
overall significance was its assessment of this surfactant-glucocorticoid mixture in a 
relevant animal model (Figure 5.4). Specifically, it demonstrated that this anti-
inflammatory surfactant, administered after an inflammatory insult, was more effective 
for reducing neutrophil-driven lung inflammation than the drug alone for both male and 
female animals. These in vivo findings have clinical significance, as they further support 
this therapy as a potential treatment for inflammatory conditions, notably ARDS. Based 
on the chapter’s findings, it is tempting to suggest that a surfactant vehicle would allow 
glucocorticoids to overcome the delivery challenges associated with ARDS and treat the 
underlying neutrophilic inflammation. However, the clinical relevance of this animal 





chapter itself, this rat model of lung inflammation did not imitate the edema or airway 
collapse observed in ARDS patients. Further, this model and its outcomes did not fulfill 
the criteria outlined by the American Thoracic Society guidelines for ARDS animal 
models [30]. Notably, the guidelines recommend achieving at least three of the following 
four criteria: 1) evidence of physiological dysfunction, 2) histological evidence of tissue 
injury, 3) alteration of the alveolar capillary barrier, and 4) the presence of an 
inflammatory response [30]. Thus, despite the supportive findings in this chapter, truly 
understanding the therapeutic potential of a surfactant delivered glucocorticoid for 










Figure 5.4. Schematic summary highlighting how the in vivo assessment of 
BLES/budesonide in Chapter 4 (relevant animal model) fits into the surfactant-based drug 
development explored throughout this thesis. 
 
5.6 Future Directions: Cathelicidins 
As mentioned above, most of the research surrounding cathelicidins, as well as 
their combination with exogenous surfactants has focused on their ability to kill AMR 
bacteria. However, their ability to regulate the immune system could also be beneficial 
for treating bacterial pneumonia. Unfortunately, it is unknown if exogenous surfactant 
inhibits the immunomodulatory properties of these peptides. Specifically, their ability to 
electrostatically bind negatively charged microbial by-products could be a potential 





2 established an in vitro model for evaluating the anti-inflammatory properties of 
therapeutics, including a cathelicidin. As such, this model could be easily modified to 
directly assess the anti-inflammatory properties of different cathelicidins alone or in 
combination with an exogenous surfactant. Based on the findings of these initial wet 
bridge experiments, as well as the extent of surfactant’s inhibitory effects, the next logical 
step would be optimization. The approach would be similar to Chapter 3, investigating 
the effect of different lipid components on the anti-inflammatory function of different 
cathelicidins, with the ultimate goal of developing a more ideal synthetic surfactant. 
Lastly, optimal surfactant-cathelicidin combinations should also be explored in vivo. 
Specifically, in a relevant animal model for pneumonia with outcomes for both their 
antimicrobial and anti-inflammatory effects.  
The goal of the wet bridge experiments should be to screen different cathelicidins 
in combination with a surfactant vehicle. However, the in vitro model could also be 
expanded. For example, the wet bridge experiments could utilize primary or alveolar 
macrophages isolated from animals or even ARDS patients. Further, a more diverse range 
of inflammatory outcomes could be measured with additional techniques. For example, 
cells and media could be collected for measuring NF-κB activation, as well as the level of 
other inflammatory cytokines (TNF-α, IL-1β, and IL-8) by qPCR and ELISA. To gain a 
better functional measurement of the inflammatory response, media could also be 
collected for a neutrophil chemotaxis assays, an approach that would require a 
chemotaxis chamber. By expanding outcomes to include a greater variety of pro-
inflammatory mediators, these experiments will further the current understanding of the 






5.5 Future Directions: Glucocorticoids In Vitro 
As mentioned previously, the biophysical analysis of synthetic surfactants in 
combination with various therapeutics could be expanded beyond the wet bridge transfer 
system. Notably, glucocorticoids, one of which was explored in vitro in Chapter 2 and in 
vivo in Chapter 4, have been shown to negatively impact the surface tension lowering 
properties of exogenous surfactants during expansion/compression cycling [31–33]. Thus, 
through the use of additional techniques that can assess surfactant function during 
expansion/compression cycling, the optimization process established in Chapter 3 could 
be expanded to create ideal synthetic surfactants for glucocorticoids. 
A common interpretation of the inhibitory effects of glucocorticoids on surfactant 
function is that they are associated with the structural similarity between glucocorticoids 
and cholesterol [31–34]. Briefly, at normal levels within pulmonary surfactant, 
cholesterol associates with DPPC containing domains and has minimal impact on 
surfactant function (Figure 5.5). In contrast, elevated cholesterol, beyond levels that will 
only interact with DPPC, will begin to alter the non-DPPC containing domains [35, 36]. 
This creates a more fluid structure, which has been shown to impair surfactant function. 
Therefore, developing a functional cholesterol-free synthetic surfactant, with a high 
DPPC concentration would be ideal for delivering glucocorticoids like budesonide. The 
basic idea being to create synthetic surfactants less susceptible to inhibition by the 







Figure 5.5. A schematic comparison of surfactant films with A) no cholesterol, B) normal 
amounts of cholesterol, and C) high amounts of cholesterol. Elevated cholesterol leads to 
surface film collapse and surfactant dysfunction.  
 
To assess this concept experimentally, techniques like the CDS could be utilized 
in addition to the wet bridge transfer system to evaluate surfactant function [37]. Like the 
optimization process for cathelicidins (Chapter 3), researchers could develop synthetic 
surfactant mixtures using individual surfactant lipids and protein mimics, creating varying 
concentrations of cholesterol and DPPC. These surfactant mixtures would then be 
evaluated on the wet bridge system for spreading and the CDS for their function during 
expansion/compression. Once functional synthetic surfactants were established, these 
biophysical techniques could then be utilized to determine the concentration dependent 
inhibitory effects of various glucocorticoids compared to cholesterol. Additionally, the 
anti-inflammatory effects of these glucocorticoids, delivered by cholesterol-free synthetic 
surfactants, could be evaluated on the wet bridge, utilizing a stimulated macrophage 
model (Chapter 2; see section 5.6 Future Directions: Cathelicidins). Lastly, to further 
explore glucocorticoid-surfactant mixtures as a therapy for ARDS, it would be 
recommended that the specific glucocorticoids, dexamethasone, methylprednisolone, and 





commercially available and have been previously utilized in clinical trials or animal study 
for ARDS (Table 1.3) [38, 39]. Thus, their optimization with a synthetic surfactant 
vehicle could result in a new arsenal of anti-inflammatory medications for ARDS to be 
tested in animal studies. 
 
5.7 Future Direction: Glucocorticoid In Vivo 
Assessing the therapeutic efficacy of glucocorticoids delivered by exogenous 
surfactants for ARDS, requires a clinically relevant animal model. ARDS is a complex 
and heterogenous disease. However, a sepsis-induced rat model, which incorporates 
mechanical ventilation would represent the clinical scenario and could expand upon the 
findings of Chapter 4.  
Experimentally, male and female rats could be given an intraperitoneal injection 
of fecal slurry solution or undergo cecal ligation and puncture surgery to induce sepsis 
[40–42]. Then rats would be connected to a rodent ventilator, with the mechanical 
ventilation settings being based on protective low tidal volume guidelines currently used 
in the clinical setting [18]. For treatments, rats on the mechanical ventilator would receive 
an intratracheal bolus of either 1) saline, 2) glucocorticoid, 3) exogenous surfactant, or 4) 
surfactant-glucocorticoid. As stated earlier, the American Thoracic Society guidelines 
recommends at least three of the following four criteria for an ARDS model: 1) evidence 
of physiological dysfunction, 2) histological evidence of tissue injury, 3) alteration of the 
alveolar capillary barrier, and 4) the presence of an inflammatory response [30]. 





To determine evidence of physiological dysfunction, it would be suggested that 
various physiologic outcomes be monitored during ventilation, including lung compliance 
and peak inspiratory rate. In addition, mean arterial pressure, heart rate and baseline blood 
gas measurements, such as arterial oxygenation could also be assessed. Like the in vivo 
experiment performed in Chapter 4, the inflammatory response within the lung could be 
evaluated by performing a BAL and freezing lung tissue. The BAL could be analyzed to 
calculate inflammatory cell counts and differentials, as well as the concentrations of 
various pro-inflammatory cytokines. The lung tissue could be homogenized for an MPO 
activity assay. However, these inflammatory outcomes could also be expanded by 
investigating with qPCR, macrophage polarization, or immunocytochemistry. For 
example, in an additional cohort of animals, lung tissue could be collected and fixed for 
immunohistochemical analysis of cellular influx (e.g. stain for Ly6B.2 to determine 
interstitial neutrophil infiltration). For assessing alterations to the alveolar-capillary 
barrier, a wet/dry ratio of the lung could be determined, in addition to the BAL being 
analyzed to determine protein levels. Vascular permeability could also be examined by 
measuring Evan’s blue albumin leak into the pulmonary tissue. For histological evidence 
of tissue injury, it would be recommended that fixed lung tissue be sectioned and scored 
by a pulmonary pathologist blinded to experimental groups. In addition, although not part 
of the recommended guidelines, we would suggest evaluating alterations in endogenous 
pulmonary surfactant function and pool size, perhaps through the utilization of the CDS, 
as well as a phosphorous assay. Lastly, there are multiple reasons for the recommendation 
of rats instead of mice for this model: 1) it would be easier to collect larger quantities of 
samples, 2) many labs, including our own lab have more experience ventilating rats, and 





44]. Together, these factors, as well as the discussed outcomes should allow this rat 
model to fulfill the American Thoracic Society guidelines and assess this novel therapy in 
a clinically relevant ARDS model.  
 
5.8 Concluding Remarks 
Based on the data accumulated throughout this thesis, we conclude that exogenous 
surfactants can be utilized to enhance the distribution and therefore efficacy of 
intrapulmonary therapeutics. Its utility as a carrier for pulmonary therapeutics makes 
intuitive sense and, more importantly, is supported by scientific evidence. Chapter 2 
showcased the newly developed wet bridge transfer system and how it could be utilized to 
study surfactant as a drug carrier, as well as screen surfactant-based therapeutics (Figure 
5.2). Chapter 3 demonstrated how customized synthetic surfactant could extend the 
delivery benefits of a surfactant vehicle to compounds previously shown to have their 
therapeutic function impaired by exogenous surfactants (Figure 5.3). Further, this chapter 
demonstrated how a more thorough understanding into the interactions of drug-surfactant 
preparations, could result in synthetic surfactants specifically designed to retain a drug’s 
function and surfactant function. Chapter 4 showed how relevant animal models could be 
utilized to expand upon the currently available in vitro tools for studying surfactant as a 
drug carrier and assess their in vivo efficacy (Figure 5.4). Together, these chapters 
outlined a process for surfactant design that integrated both in vitro and in vivo studies, 
enhanced the understanding of surfactant as a drug carrier, and allowed for continuous 





that this integrative approach will be essential to translate the basic idea of surfactant as a 
carrier for pulmonary drugs toward clinical trials and ultimately clinical practise.   
To illustrate the concepts associated with surfactant-based drug delivery the 
experiments within this thesis focused on bactericidal compounds (cathelicidins) for 
pneumonia and anti-inflammatory agents (glucocorticoids) for ARDS. However, the 
potential drug targets for these conditions are not limited to antimicrobial and anti-
inflammatory agents. For example, a β2 agonist to reduce edema formation associated 
with ARDS has been investigated [45, 46]. Unfortunately, meta-analysis of the data did 
not show a benefit of the drug and, in fact, indicated the potential of detrimental effects 
[47]. Although other conclusions are feasible, inadequate drug delivery to the target site 
may have contributed to these undesirable results. Specifically related to the β2 agonist, 
delivery of this drug via aerosol will unlikely reach the edematous areas of the lung where 
the drug is required. Revisiting this drug, and concept of reducing edema in ARDS, by 
studying its combination with surfactant has the potential for different outcomes. This 
concept may apply not just to β2 agonists, but also to the many other pharmacological 
agents that have been unsuccessfully tried in patients with pneumonia or ARDS [19, 48, 
49]. Additionally, whereas this thesis primarily focused on bacterial pneumonia and 
ARDS as potential clinical targets, it should also be noted that other pulmonary diseases 
may be equally appropriate for the utilization of surfactant-based therapies. For example, 
drugs for pulmonary fibrosis or emphysema, marked by a thickening and destruction of 
the alveolar walls respectively, may be potential targets for such investigations. Further, 
one can also imagine delivery of other components, for example contrast agents for 





are certain that surfactant as a vehicle for various drugs and other compounds is a 
promising approach in a variety of circumstances requiring pulmonary delivery.    
Lastly, this thesis provided strong in vitro and in vivo data supporting the more 
targeted use of cathelicidin- and glucocorticoid-fortified surfactants in patients afflicted 
with bacterial pneumonia or ARDS. For cathelicidin-fortified surfactants, the 
combination is clearly a bit behind in its development towards clinical trials compared to 
glucocorticoids. However, based on the strong scientific data presented throughout this 
thesis, they clearly have potential and should be explored in relevant animal models. For 
glucocorticoids, the data from our thesis implies that that the combinatorial effect of 
exogenous surfactant with these drugs may overcome the limitations of those observed 
for each therapy, in previous clinical trials [50–57]. As such, the next logical step for the 
developmental process presented in this thesis would be to assess the combination in 
large animal models and design phase 1 or 2 clinical trials. The assessment of this 
therapeutic combination in clinical trial is also supported by the ongoing trials of 
surfactant therapy to treat COVID-19 patients and surfactant-glucocorticoid combination 
in infants [58–62]. Simply put, the glucocorticoid-surfactant approach is a repurposing of 
two clinically approved drugs that are currently utilized in humans [63, 64]. Thus, the 
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